PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:
A23K 1/165

A1

(11) International Publication Number: WO 95/16360

(43) International Publication Date: 22 June 1995 (22.06.95)

(21) International Application Number: PCT/EP94/04212

(22) International Filing Date: 19 December 1994 (19.12.94)

(30) Priority Data:

08/169,948

17 December 1993 (17.12.93) US

(71) Applicants (for all designated States except US): FINNFEEDS INTERNATIONAL LIMITED [GB/GB]; Market House, Ailesbury Court, High Street, Marlborough, Wiltshire SN8 1AA (GB). GENENCOR INTERNATIONAL INC. [US/US]; 4 Cambridge Place, 1870 Winton Road South, Rochester, NY 14618 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BEDFORD, Michael, Richard [GB/GB]; Finnfeeds International Limited, Market House, Ailesbury Court, High Street, Marlborough, Wiltshire SN8 1AA (GB). MORGAN, Andrew, John [GB/GB]; Finnfeeds International Limited, Market House, Ailesbury Court, High Street, Marlborough, Wiltshire SN8 1AA (GB). FOWLER, Timothy [US/US]; Nr. 304, 1000 Continental Way, Belmont, CA 94002 (US). CLARKSON, Kathleen, A. [US/US]; 53 28th Street, San Francisco, CA 94110 (US). WARD, Michael [US/US]; 4372 24th Street, San Francisco, CA 94114 (US). COLLIER, Katherine, D. [US/US]; 658

Oakpark Way, Redwood City, CA 94062 (US). LARENAS, Edmund [US/US]; 352 Caprino Way, San Carlos, CA 94070 (US).

(74) Agents: HANSEN, Bernd et al.; Hoffmann, Eitle & Partner, Arabellastrasse 4, D-81925 München (DE).

(81) Designated States: AU, CA, CN, CZ, FI, HU, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: AN ENZYME FEED ADDITIVE AND ANIMAL FEED INCLUDING IT

(57) Abstract

The use is provided of a composition as a feed additive which comprises one or more endoglucanases, and 0-20 % by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase. The endoglycanases may be one or more of EGI, EGII, EGIII and any functionally active derivative of any thereof. Such endoglucanases may be obtained from a genetically modified strain of the fungus *Trichoderma*. Also provided is an enzyme-based feed additive which comprises EGI and/or EGII which lack the cellulose binding domain, and 0-20 % by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. A further enzyme-based feed additive is provided which comprises a cereal-based carrier, one or more endoglucanases, and 0-20 % by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. Such enzyme-based feed additives can be incorporated into a cereal-based feed which includes one or more of barley, wheat, triticale, rye and maize. The feed additive has the advantage of improving the feed conversion ratio and/or increasing the digestibility of a cereal-based feed in which it is included.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	II	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RÜ	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	SD	Sudan
CG	Congo		of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon		•		

AN ENZYME FEED ADDITIVE AND ANIMAL FEED INCLUDING IT

The present invention relates to an enzyme feed additive, and in particular to such an additive which can decrease the feed conversion ratio of a cereal-based feed and/or increase its digestibility.

Improvements in animal feeds to enable animals to digest them more efficiently are constantly being sought. One of the main concerns is to improve the feed conversion ratio (FCR) of a feed without increasing its cost per unit weight. The FCR is the ratio of the amount of feed consumed relative to the weight gain of an animal. A low FCR indicates that a given amount of feed results in a growing animal gaining proportionately more weight. This means that the animal is able to utilise the feed more efficiently. One way in which the FCR of a feed can be improved is to increase its digestibility.

There are various constraints on the digestibility of the nutritional components of a feed such as its starch, fat, protein and amino acid content. These constraints include:

- (i) the viscosity of materials present in the animal's gut. Such viscosity is due, at least in part, to soluble non-starch polysaccharides such as mixed-linked β -glucans and arabinoxylans;
- (ii) entrapment of nutrients within the cell walls of the feed, particularly those of the aleurone

- 2 -

layer in cereals. Such entrapment is caused by the high levels of non-starch polysaccharides in the cell walls of cereals which are relatively resistant to break-down by the animal's digestive system. This prevents the nutrients entrapped within the cells from being nutritionally available to the animal; and

(iii) a deficiency in endogenous enzyme activity, both of the animal and of the gut microbial population particularly in a young animal.

The above problems which interfere with digestibility are particularly noticeable in the case of cereal-based diets, and in particular those having a high barley content.

Due to the problem of poor digestibility of nutrients from the feed, it is normally necessary to formulate feeds to contain higher levels of energy providing materials in order to meet the nutritional demands of animals. Such energy providing materials conventionally include starch, fat, sugars, fibre etc. The requirement of including these energy providing materials, or sources of such materials, in a feed adds a considerable extra cost which is disadvantageous from an economic view point.

In an attempt to solve the problem of poor digestibility of cereal-based feeds, it is known to include enzyme supplements such as β -glucanases or xylanases in animal feeds. For example, WO 91/04673 discloses a feed

- 3 -

additive for alleviating malabsorption syndrome in poultry which causes reduced digestion. The additive irreludes a cellulase and a xylanase. JP-A-60-75238 discloses a feed for domestic animals which contains an enzyme cocktail including protease-, cellulase-, amylase- and lipase-activities. This reference speculates that these various enzyme activities enable fermentation microbes to grow and that these become useful nutritional components of the feed.

Whole cellulase is a mixture of different enzymes which cooperate to hydrolyze cellulose (β -1,4-D-glucan linkages) and/or derivatives thereof (e.g. phosphoric acid swollen cellulose) and give as primary products compounds such as glucose, cellobiose, and cellooligo-saccharides. Whole cellulase is made up of several different enzyme classifications including enzymes having exo-cellobiohydrolase activity, endoglucanase activity and β -glucosidase activity.

For example, the whole cellulase produced by the fungus Trichoderma longibrachiatum comprises two exocellobiohydrolases, CBHI and CBHII, at least endoglucanases, EGI, EGII and EGIII, and at least one β glucosidase. Α representative fermentation T.longibrachiatum may produce a whole cellulase including by protein weight 45-55% CBHI, 13-15% CBHII, 11-13% EGI, 8-10% EGII, 1-4% EGIII and 0.5-1% BG. However, it should be noted that actual concentrations of а cellulase component will vary according to numerous factors, including fermentation conditions, concentrations and strain type. Thus, in

- 4 -

representative fermentation, *Trichoderma longibrachiatum* prooduces a whole cellulase having from 58-70% of cellobiohydrolases.

Each endoglucanase of *T. longibrachiatum* has its own distinct characteristics. Thus, EGI in addition to cellulase activity is known to hydrolyze xylan. EGII and EGIII by comparison do not show significant xylanase activity, at least according to azo-xylan native PAGE overlay. Further, it is known that EGI, EGII and EGV contain structurally distinct cellulose binding domains (CBD's). On the other hand, EGIII does not appear to contain a structurally distinct binding domain and has been shown to have a lower affinity for crystalline cellulose compared to EGI or EGII.

WO 92/06209 discloses processes for transforming the filamentous fungus Trichoderma reesei (now called "T. longibrachiatum") which involves the steps of treating a T. reesei strain with substantially homologous linear recombinant DNA to permit homologous transformation and then selecting the resulting T. reesei transformants. instance, transformants are described in which certain targeted genes are deleted or disrupted within the genome and extra copies of certain native genes such EGI EGII those encoding and are homologously recombined into the strain. It is noted in this reference that cellulase compositions obtained from strains deficient in CBHI and CBHII components are useful as components of a detergent cleaning composition. cellulase compositions are of course relatively enriched

- 5 -

When used in vivo, endoglucanases and cellobiohydrolases are considered to act synergistically in the hydrolysis of cellulose to small cello-oligosaccharides (mainly cellobiose), which are subsequently hydrolysed to glucose β-glucosidase. In action of addition hydrolyzing the β -1,4 linkages in cellulose, endo-1,4- β glucanase (EC 3.2.1.4) will also hydrolyze 1,4 linkages β -glucans also containing 1,3-linkages. The in endoglucanases act on internal linkages to produce cellobiose, glucose and cello-oligosaccharides. cellobiohydrolases act on the chain ends of cellulose polymers to produce cellobiose as the principal product.

Whole cellulase obtained from T. longibrachiatum has been used in combination with barley in fields such as brewing and in animal nutrition for several years. One of the benefits of adding cellulases to barley-based diets for livestock is to increase the digestibility of various components present in the diet including protein and amino acids. As a result, dietary input costs can be reduced without loss of performance, and excretion of nitrogen in the manure can be significantly reduced. This reduces the environmental impact of intensive livestock farming.

Endosperm cell walls of barley contain a high proportion of high molecular weight, water-soluble mixed-linked β -(1,3)(1,4)-glucans. When solubilised, these polysaccharides cause an increase in the solution's viscosity. For example, if barley is fed to broiler chickens, this leads to a relatively high level of

- 6 -

viscosity in the region of their gastrointestinal tract, which results in reduced efficiency of digestion and growth depression.

Organisms which produce or express cellulase enzyme complexes often also express xylanase activity. For example, two different xylanase enzymes produced by T. longibrachiatum have been identified. The purification of these two different xylanases, one referred to as high pI xylanase (having a pI of about 9.0) and the other referred to as low pI xylanase (having a pI of about 5.2), as well as the cloning and sequencing of the gene for each xylanase is described in detail in WO 92/06209 and WO 93/24621. Figure 16 of this document sets out the deduced amino acid sequences for both the low pI and high pI gene products. Example 22 also teaches how to create T. longibrachiatum strains which over-express the low pI and high pI xylanase genes.

As mentioned above, the use of cellulases as an additive to animal feeds is known in the art. Such cellulases of course possess a natural balance between their cellobiohydrolase and endoglucanase contents. As also mentioned above, in naturally occurring strains of T. longibrachiatum, the CBHs may comprise 58-70% by weight of the cellulase proteins.

The present invention is based upon a study to identify which components of the cellulase proteins are able to improve the nutritional benefits of cereal-based feeds such as those including barley. Specific attention has been paid to the effects of the individual enzymes

- 7 -

constituting whole cellulase, and in particular the endoglucanases, on viscosity reduction of soluble mixed-linked β -(1,3)(1,4)-glucans of barley. This is because this is known to be one of the primary modes of action of whole cellulase. The present invention has been made as a result of this research to identify those specific components of the cellulase enzyme system, and their relative amounts, which advantageously improve the feed conversion ratio (FCR) of a cereal-based feed and/or increase its digestibility.

In the description and claims which follow, the following are definitions of some of the technical terms which are employed.

"Fungal cellulase" means an enzyme composition derived from fungal sources or microorganisms genetically modified so as to incorporate and express all or part of the cellulase genes obtained from a fungal source.

The term "Trichoderma" refers to any fungal strain which is or has previously been classified as Trichoderma or which is currently classified as Trichoderma. Such species include Trichoderma longibrachiatum, Trichoderma reesei and Trichoderma viride.

The term "EG" refers to any endoglucanase, for example EGI, EGII, EGIII or EGV produced by T. longibrachiatum, or any derivative of any such endoglucanase which possesses endoglucanase activity.

- 8 -

An EG "derivative" includes for example, EGI, EGII, EGIII and EGV from Trichoderma in which there is an addition of one or more amino acids to either or both of the C- and N- terminal ends of the EG, a substitution of one or more amino acids at one or more sites throughout the EG, a deletion of one or more amino acids within or at either or both ends of the EG, or an insertion of one or more amino acids at one or more sites in the EG such that endoglucanase activity is retained in the derivatized EG. The term EG "derivative" also includes the core domains of the endoglucanase enzymes that have attached thereto one or more amino acids from the linker regions.

The term "truncated cellulase", as used herein, refers to a protein comprising a truncated cellulase core of exocellobiohydrolase or endoglucanase, for example, EGI, EGII, EGV, CBHI and CBHII, or derivatives of either. EGV is described in Molecular Microbiology, Vol. 13, No. 2 (1994) at pages 219-228. As stated above, many cellulase enzymes, such as EGI, EGII and EGV, are believed to be bifunctional in that they contain regions or domains which are directed toward both catalytic or hydrolytic activity with respect to the cellulose substrate, and also non-catalytic cellulose binding activity. Thus, a truncated cellulase is a cellulase which lacks binding domain cellulose binding activity.

It is believed that the catalytic core and the cellulose binding domain of a cellulose enzyme act together in a synergistic manner to effect efficient hydrolysis of cellulose fibers in a cellulose containing feed. It is

- 9 -

further believed that cellulase catalytic activity and cellulose binding activity may be identified as being specific to distinct structural regions, or present in the same structural region. For example, as indicated above, many cellulase enzymes, several of those from T. longibrachiatum are known to incorporate a catalytic core domain subunit which is attached via a linker region to a cellulose binding domain subunit. However, other cellulase enzymes are believed to have a catalytic core domain which is structurally integral to a cellulose binding domain, e.g., the two regions are not separated by a linker and do not represent distinct structural entities. cellulase enzyme, it is believed that a specific peptide group of related amino acid residues may responsible for cellulose binding activity. Accordingly, it is within the scope of the present invention that such a binding domain would be altered so as to reduce the cellulose binding activity of the cellulase by, example, genetic engineering or chemical modification.

"truncated cellulase derivative" encompasses truncated cellulase core, as defined herein, there may be an addition or deletion of one or more amino acids to either or both of the C- and N- terminal ends of the truncated cellulase, or a substitution, insertion or celetion of one or more amino acids at one or more sites throughout the truncated cellulase. Derivatives are interpreted to include mutants that preserve their character as truncated cellulase core, as defined below. It is also intended that the term "derivative of a truncated cellulase" includes core domains of the

- 10 -

exoglucanase or endoglucanase enzymes that have attached thereto one or more amino acids from the linker regions.

A truncated cellulase derivative further refers to a protein substantially similar in structure and biological activity to a truncated cellulase core domain protein, but which has been genetically engineered to contain a modified amino acid sequence. Thus, provided that the two proteins possess a similar activity, they are considered "derivatives" as that term is used herein even if the primary structure of one protein does not possess the identical amino acid sequence to that found in the other.

It is contemplated that a truncated cellulase derivative may be derived from a DNA fragment encoding a truncated catalytic core domain which further contains an addition of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment, a deletion of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment or a substitution of one or more nucleotides internally or at the 5' or 3' end of the DNA fragment wherein the functional activity of the catalytic core domain (truncated cellulase derivative) is retained. Such a DNA fragment ("variant DNA fragment") comprising a cellulase catalytic core may further include a linker or hinge DNA sequence or portion thereof which is attached to the core or binding domain DNA sequence at either the 5' or 3' end wherein the functional activity of the encoded truncated cellulase core domain (truncated cellulase derivative) is retained.

The term "truncated cellulase core" or "truncated cellulase region" refers herein to a peptide comprising

- 11 -

the catalytic core domain or region of exocellobiohydrolase or endoglucanase, for example, EGI, EGII or EGIII or a derivative thereof that is capable of enzymatically cleaving cellulose polymers, including but not limited to pulp or phosphoric acid swollen cellulose. However, a truncated cellulase core will not possess cellulose binding activity attributable to a cellulose binding domain or region. A truncated cellulase core is distinguished from a non-truncated cellulase which, in an intact form, possesses no cellulose binding domain or A truncated cellulase core may include other region. entities which do not include cellulose binding activity attributable to cellulose binding domain or region. example, the presence of linker a orhinge is specifically contemplated. Similarly the covalent attachment of another enzymatic entity to the truncated cellulase core is also specifically contemplated.

The performance (or activity) of a protein containing a truncated catalytic core or a derivative thereof may be determined by methods well known in the art. (See Wood, T.M. et al. in Methods in Enzymology, Vol. 160, Editors: Wood, W.A. and Kellogg, S.T., Academic Press, pp. 87-116, 1988). For example, such activities can be determined by hydrolysis of phosphoric acid-swollen cellulose and/or soluble oligosaccharides followed by quantification of the reducing sugars released. In this case the soluble sugar products, released by the action cellobiohydrolase or endoglucanase cellulase core domains or derivatives thereof, can be detected by HPLC analysis or by use of colorimetric assays for measuring reducing sugars. It is expected that these catalytic domains or

WO 95/16360 PCT/EP94/04212 - 12 -

derivatives thereof will retain at least 10% of the activity exhibited by the intact enzyme when each is assayed under similar conditions and dosed based on similar amounts of catalytic domain protein.

The term "cellulose binding domain" refers herein to an amino acid sequence of the endoglucanase comprising the binding domain of an endoglucanase, for example, EGI or EGII, that non-covalently binds to a polysaccharide such as cellulose. It is believed that cellulose binding domains (CBDs) function independently from the catalytic core of the endoglucanase enzyme to attach the protein to cellulose. Truncated endoglucanases used in this invention lack the CBD but include at least the core or catalytic domain.

The term "linker region" or "hinge region" refers to the short peptide region that links together the two distinct functional domains of the fungal endoglucanases, i.e., the core domain and the binding domain. These domains in T. longibrachiatum cellulases are linked by a peptide rich in Ser, Thr and Pro.

A "signal sequence" refers to any sequence of amino acids bound to the N-terminal portion of a protein which facilitates the secretion of the mature form of the protein outside of the cell. This definition of a signal sequence is a functional one. The mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.

WO 95/16360 PCT/EP94/04212 - 13 -

The term "host cell" means both the cells and protoplasts created from the cells of *Trichoderma*.

The term "DNA construct or vector" (used interchangeably herein) refers to a vector which comprises one or more DNA fragments or DNA variant fragments encoding any one of the truncated endoglucanases or derivatives described above.

The term "functionally attached to" means that a regulatory region, such as a promoter, terminator, secretion signal or enhancer region is attached to a structural gene and controls the expression of that gene.

The term "whole cellulase" means the complete cellulase system as produced by a naturally occurring microorganism.

Based upon the above considerations, it is an object of the present invention to provide enzyme-based feed additives which improve the FCR and/or increase the digestibility of a cereal-based feed.

According to one aspect, the present invention provides the use of a composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase.

As mentioned above, whole cellulase from T. longibrachiatum (i.e. strains occurring naturally) typically contains 58-70% by weight of cellobiohydrolases

or more based on the total weight of enzymes having cellulase activity. The composition for use as a feed additive provided by the present invention may obtained by enriching the content of endoglucanases produced by a suitable microorganism purification, addition of purified endoglucanase or adding additional genes to overproduce endoglucanase. addition, or alternatively, the relative content cellobiohydrolases produced by the microorganism may be decreased compared to whole cellulase through purification procedures or by modifying or deleting those genes which encode cellobiohydrolase. It is particularly preferred that the feed additive should be free of cellobiohydrolases, so that their content in the additive is 0% by weight.

In a second aspect, the present invention provides an enzyme-based feed additive which comprises at least one of EGIII, EGI which lacks the cellulose binding domain and EGII which lacks the cellulose binding domain, and 0-20% by weight based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.

The production of such structurally modified endoglucanases by genetic engineering techniques is described in detail below.

In a third aspect, the present invention provides an enzyme-based feed additive comprising a cereal-based carrier, one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase. In such an additive,

- 15 -

the cereal-based carrier may be milled wheat, maize or milled soya. Further, the carrier may be a by-product of any of these materials.

Endoglucanases suitable for use in the present invention those derived from bacterial include sources, example, Bacillus sp., including Bacillus subtilis, Streptomyces sp., Clostridium sp., including Clostridium thermocellum and Clostridium cellulovorans. Alternatively, fungal sources of cellulase are suitable. Suitable fungal sources include Trichoderma Trichoderma longibrachiatum, Trichoderma viride, Trichoderma koningii, Myceliophthora sp., Phanerochaete sp., Schizophyllum sp., Penicillium sp., Aspergillus sp., Geotricum sp., Fusarium sp., Fusarium oxysporum, Humicola sp., Humicola insolens, and Mucor sp., including Mucor miehei.

Endoglucanase type components may not include components traditionally classified as endoglucanases using activity tests such as the ability of the component (a) hydrolyze soluble cellulose derivatives as (CMC), thereby reducing carboxymethylcellulose viscosity of CMC containing solutions, (b) to readily hydrolyze hydrated forms of cellulose such as phosphoric acid, swollen cellulose (e.g., Walseth cellulose) and hydrolyze less readily the more highly crystalline forms of cellulose (e.g., Avicel, Solkafloc, etc.). other hand, it is believed that not all endoglucanase components, as defined by such activity tests, will enhance the nutritional value of feeds. Accordingly, it is more accurate for the purposes herein to define endoglucanase type components as those enzymes which

possess feed nutritional enhancement properties comparable to those possessed by the endoglucanase components of *Trichoderma longibrachiatum*.

- 16 -

Fungal cellulases can contain more than one endoglucanase type component. The different components generally have isoelectric points, different different weights, different degrees of glycosylation, different substrate specificities, different enzymatic patterns, etc. The different isoelectric points of the components allow for their separation via ion exchange chromatography and the like. In fact, the isolation of components from different sources is known in the art. See, for example Bjork et al., U.S. Patent No. 5,120,463; Schulein et al., International Application WO 89/09259; Wood et al., Biochemistry and Genetics of Cellulose Degradation, pp. 31-52 (1988); Wood et al., Carbohydrate Research, Vol. 190, pp. 279-297 (1989); and Schulein, Methods in Enzymology, Vol. 160, pp. 234-242 (1988). The entire disclosure of each of these references incorpoated herein by reference.

The term "EGI cellulase" refers to the endoglucanase component derived from Trichoderma longibrachiatum spp. characterized by a pH optimum of about 4.0 to 6.0, an isoelectric point (pI) of from about 4.5 to 4.7, and molecular weight of about 47 to 49 Kdaltons. EGI cellulase is derived from either Trichoderma longibrachiatum Trichoderma orfrom viride. EGI cellulase derived from Trichoderma longibrachiatum has a pH optimum of about 5.0, an isoelectric point (pI) of about 4.7 and a molecular weight of about 47 to 49

- 17 -

Kdaltons. EGI cellulase dervied from *Trichoderma viride* has a pH optimum of about 5.0, an isoelectric point (pI) of about 5.3 and a molecular weight of about 50 Kdaltons.

It is noted that EGII has previously been referred to as "EGIII" by some authors but current nomenclature uses the term EGII. In any event the EGII protein differs substantially from the EGIII protein in its molecular weight, pI and pH optimum. The term "EGII cellulase" refers to the endoglucanase component derived from Trichoderma spp. characterized by a pH optimum of about 4.0 to 6.0, an isoelectric point (pI) of about 5.5, and a molecular weight of about 35 Kdaltons. Preferably, EGII cellulase is derived from either Trichoderma longibrachiatum or from Trichoderma viride.

The term "EGIII cellulase" refers to the endoglucanase component derived from Trichoderma spp. characterized by a pH optimum of about 5.0 to 7.0, an isoelectric point (pI) of from about 7.2 to 8.0, and a molecular weight of about 23 to 28 Kdaltons. Preferably, EGIII cellulase is derived from either Trichoderma longibrachiatum or from Trichoderma viride. EGIII cellulase derived from Trichoderma longibrachiatum has a pH optimum of about 5.5 to 6.0, an isoelectric point (pI) of about 7.4 and a molecular weight of about 25 to 28 Kdaltons. EGIII cellulase derived from Trichoderma viride has a pH optimum of about 5.5, an isoelectric point (pI) of about 7.7, and a molecular weight of about 23.5 Kdaltons.

"Exo-cellobiohydrolase type components" ("CBH type components") refers to all those cellulase components

which exhibit similar feed activity properties to CBHI and CBHII of *Trichoderma longibrachiatum*. In this regard, when used in combination with EG type components, CBHI and CBHII type components (as defined above) reduce

- 18 -

the effectiveness of a cellulase supplement for animal feed in terms of the feed conversion ratio and/or feed digestibility.

exo-cellobiohydrolase type components not include components traditionally classed as exocellobiohydrolases using activity tests such as those used to characterize CBHI and CBHII from Trichoderma longibrachiatum. For example, such components (a) are competitively inhibited by cellobiose (K; approximately 1mM); (b) are unable to hydrolyze to any significant degree substituted celluloses, such as carboxymethylcellulose, etc., and (c) hydrolyze phosphoric acid swollen cellulose and to a lesser degree highly crystalline cellulose. On the other hand, it is believed that some cellulase components which characterized as CBH components by such activity tests, will enhance the nutritional value of Accordingly, it is believed to be more accurate for the purposes herein to define such exo-cellobiohydrolases as EG type components because these components possess similar functional properties in animal uses comparable to those of the endoglucanase components of Trichoderma longibrachiatum.

" β -glucosidase (BG) components" refer to those components of cellulase which exhibit BG activity; that is to say that such components will act from the non-reducing end

- 19 -

of cellobiose and other soluble cellooligosaccharides ("cellobiose") and give glucose as the sole product. components do not adsorb onto or react with cellulose Furthermore, such ВG components competitvely inhibited by glucose (Ki approximately 1mM). While in a strict sense, BG components are not literally cellulases because they cannot degrade cellulose, such BG components are included within the definition of cellulase system because these enzymes facilitate overall degradation of cellulose by further degrading the inhibitory cellulose degradation products (particularly cellobiose) produced by the combined action of components and EG components. Without the presence of BG components, moderate or little hydrolysis of crystalline cellulose will occur. BG components are often characterized by using aryl substrates such pnitrophenol- β -D-glucoside (PNPG) and thus are often called aryl-glucosidases. It should be noted that not all aryl-glucosidases are BG components, in that some do not hydrolyze cellobiose.

It is contemplated that the presence or absence of BG components in the cellulase composition can be used to regulate the activity of any CBH components the composition. Specifically, because cellobiose produced during cellulose degradation by CBH components, and because high concentrations of cellobiose are known CBH activity, inhibit and further because cellobiose is hydrolyzed to glucose by BG components, the absence of BG components in the cellulase composition will "turn-off" CBH activity when the concentration of cellobiose reaches inhibitory levels. Ιt is also

- 20 -

contemplated that one or more additives (e.g., cellobiose, glucose, etc.) can be added to the cellulase composition to effectively "turn-off", directly or indirectly, some or all of the CBHI type activity as well as other CBH activity. When such additives are employed, the resulting composition is considered to be a composition suitable for use in this invention if the amount of additive is sufficient to lower the CBH type activity to levels equal to or less than the CBH type activity levels achieved by using the cellulase compositions described herein.

On the other hand, a cellulase composition containing added amounts of BG components may increase overall hydrolysis of cellulose if the level of cellulose generated by the CBH components becomes restrictive of such overall hydrolysis in the absence of added BG components.

Methods to either increase or decrease the amount of BG components in the cellulase composition are disclosed in U.S. Serial No. 07/807,028 filed December 10, 1991 which is a continuation-in-part of U.S. Serial No. 07/625,140, filed December 10, 1990 (corresponding to EP-A-0 562 003), all of which are incorporated herein by reference in their entirety.

Fungal cellulases can contain more than one BG component. The different components generally have different isoelectric points which allow for their separation via ion exchange chromatography and the like. Either a

- 21 -

single BG component or a combination of BG components can be employed.

In a preferred embodiment, the endoglucanase components suitable for use in the present invention are those which exhibit properties similar to those obtainable from Trichoderma longibrachiatum, i.e., EGI, EGII and EGIII. Thus, the term "EG type components" refers to all of those cellulase components or combination of components which confer improved properties to feed in a manner similar to the endoglucanase components of Trichoderma longibrachiatum. In this regard, the endoqlucanase components of Trichoderma longibrachiatum (specifically, EGI, EGII, EGIII and the like, either alone or in combination) impart characteristics such as improved feed conversion ratio, reduced gut viscosity and improved animal weight gain to animals fed grains treated with them as compared to untreated feed, or feed treated with whole cellulase. Methods for the preparation of EGI, EGII and EGIII are described in detail in WO 92/06209.

It is possible that components other than CBH type components present in the whole cellulase composition may cause undesirable gut viscosity, feed conversion ratio increase and lessened animal weight gain. Therefore, it is contemplated that the use of enriched endoglucanases, such as EGI, EGII or EGIII, may eliminate some or all of the problems which occur when whole cellulase is used.

- 22 -

It has been found that the inclusion of an endoglucanse enriched feed additive in a cereal-based diet of an animal enables the animal to digest the diet more efficiently. This is particularly the case in cereal-based feeds including barley where the presence of the above feed additive improves the feed conversion ratio and/or increases the digestibility of the cereal-based feed. Cereal-based feeds usually include at least 25% by weight of cereal and preferably at least 35% by weight. In addition to or instead of barley, the cereal may include one or more of wheat, triticale, rye and maize.

The endoglucanase enriched feed additives provided by the present invention also enable a conventional cereal-based feed to be modified by reducing its energy, and/or protein, and/or amino acid content whilst simultaneously maintaining the same nutritional levels of energy, protein, and amino acids available to the animal. means that the amounts of costly energy and protein supplements conventionally included in an animal feed can be reduced as compared to conventional feeds. Energy supplements include fat. Protein supplements include fish-meal, wheat-meal, soya-bean, rapeseed, or canola. This results in a significant reduction in the cost per unit weight of the animal feed without decreasing its nutritional value. Alternatively, or even additionally, the amounts of amino acid supplements can be reduced as compared to conventional feeds which can also result in significant cost savings.

The enzyme feed additive according to the present invention can be prepared in a number of ways. For

- 23 -

instance, it can be prepared simply by mixing different enzymes having the appropriate activities to produce an enzyme mix. This enzyme mix can be either mixed directly with a feed, or more conventionally impregnated onto a cereal-based carrier material such as milled wheat, maize or soya flour. A by-product of any of these products may also be used. Such an impregnated carrier constitutes an enzyme feed additive in accordance with the third aspect of the present invention.

As an alternative, a cereal-based carrier formed from e.g. milled wheat or maize can be impregnated either simultaneously or sequentially with enzymes having the appropriate activities. For example, a milled wheat carrier may be sprayed with the one or more endoglucanases. Other enzymes may also be incorporated as appropriate. The carrier material impregnated with these enzymes also constitutes an enzyme feed additive accordance with the third aspect of the present invention.

The feed additive provided by the present invention may be mixed directly with the animal feed, such as one comprising barley, to prepare the final feed. Alternatively, the feed additive may be mixed with one or more other feed additives such as a vitamin feed additive, a mineral feed additive and an amino acid feed additive. The resulting feed additive including several different types of components can then be mixed in an appropriate amount with the feed.

- 24 -

The resulting cereal-based feed preferably comprises 0.000001-0.1 g/kg of total endoglucanases, more preferably 0.00001-0.01 g/kg and most preferably 0.0001-0.001 g/kg.

The endoglucanases for use in the feed additive of the present invention can be obtained by growing a fungus such as a naturally occurring strain of *Trichoderma*. Thus, the fungus can be cultivated, after which it is removed from the broth. The cellulase enzyme complex can then be isolated from the broth and separated into its individual components from which the endoglucanases are in turn isolated. This technique is however not so preferred because of the purification steps necessary.

A more preferred method of preparing the enzyme feed additive of the present invention is to construct by genetic manipulation a host microorganism, such as the fungus Trichoderma, which produces the desired enzymes in the appropriate relative amounts. This can be done for instance by increasing the copy number of the gene encoding endoglucanases (e.g. EGI, EGII and/or EGIII) and/or by using a suitably strong promoter in front of any of the above endoglucanase genes. Alternatively or additionally the host strain can be deleted for certain cellulase genes (e.g. those encoding CBHI and/or CBHII). Such procedures are fully explained in the disclosure of WO 92/06209 in the case of transforming T. reesei.

The enzyme feed additive provided by the present invention may also include other enzymes such as xylanase, protease, $\alpha-amylase$, glucoamylase, lipase,

- 25 -

pectinase, mannanase, α -galactosidase, αarabinofuranosidase or phytase. Enzymes having the desired activities may for instance be mixed with the endoglucanases used in the present invention either before impregnating these on a cereal-based carrier or alternatively such enzymes may be impregnated simultaneously or sequentially on such a cereal-based The carrier is then in turn mixed with a cereal-based feed to prepare the final feed. It is also possible to formulate the enzyme feed additive as a solution of the individual enzyme activities and then mix this solution with a feed material pre-formed as pellets or as a mash.

It is also possible to include the enzyme feed additive in the animals' diet by incorporating it into a second (and different) feed or drinking water which the animal also has access to. Accordingly, it is not essential that the enzyme mix provided by the present invention is incorporated into the cereal-based food itself, although such incorporation forms a particularly preferred aspect of the present invention.

In one preferred embodiment, the xylanase added as an additional enzyme is the high pI xylanase and/or the low pI xylanase obtainable from *T. longibrachiatum* obtainable by the method of Example 22 of WO 92/06209. It is particularly preferred that the xylanase is the high pI xylanase.

According to a further preferred embodiment, the protease added as an additional enzyme is a subtilisin or mutant

thereof derived from the genus *Bacillus*. Suitable strains of *Bacillus* include but are not limited to *B*. amyloliquefaciens, *B*. lentus, *B*. licheniformis, *B*. subtilis, or *B*. alcalophilus.

The subtilisin may also be a mutant subtilisin having an amino acid sequence not found in nature but which is derived from a precursor subtilisin by inserting, deleting or replacing one or more different amino acid residues in the precursor subtilisin. Suitable mutant subtilisins are described in EP-A-0 130 756 corresponding to US-Re-34686 (including mutations at positions +155, +104, +222, +166, +133, +169, +189, +217, +156, +152); EP-A-0 251 446; WO 91/06637 etc. The most preferred subtilisin is a mutant subtilisin which comprises a substitution at the amino acid residue position equivalent to tyr+217 of B. amyloliquefaciens subtilisin with leucine.

Methods of producing such mutant subtilisins are described in detail in the publications US-Re-34606 and EP-A-0 251 446.

The cereal-based animal feeds including the additive of the present invention are suitable for animals such as pigs, ruminants such as sheep and cows, and poultry such as chickens, turkeys, geese and ducks. The feeds though are particularly suitable for poultry and pigs, and in particular broiler chickens.

As previously mentioned, the enzyme feed additive according to the present invention is preferably obtained

- 27 -

by growing a genetically modified strain of the fungus Trichoderma. This is because of its well known capacity to secrete whole cellulases in large quantities. This modified strain may be derived from T. longibrachiatum, T. reesei or T. viride. The genome of such strains can be modified to over-express or delete one or more of the enzyme components making up whole cellulase.

Microorganism cultures are grown to a stationary phase, filtered to remove the cells and the remaining supernatant is concentrated by ultrafiltration to obtain the endoglucanase or derivative thereof.

In a particular aspect of the above method, the medium used to cultivate the transformed host cells may be any suitable for endoglucanase production in Trichoderma. The endoglucanase or derivative thereof is recovered from the medium by conventional techniques including separation of the cells from the medium by centrifugation, or filtration, precipitation proteins in the supernatant or filtrate with salt, for example, ammonium sulphate, followed by chromatography procedures such as ion exchange chromatography, affinity chromatography and the like.

Alternatively, the final protein product may be isolated and purified by binding to a polysaccharide substrate or antibody matrix. The antibodies (polyclonal or monoclonal) may be raised against endoglucanase core domain peptides, or synthetic peptides may be prepared from portions of the core domain and used to raise polyclonal antibodies.

- 28 -

It is further contemplated by the present invention that the DNA fragment or variant DNA fragment encoding the endoglucanase or derivative may be functionally attached to a fungal promoter sequence, for example, the promoter of the cbhl or egll gene. Also contemplated by the present invention is manipulation of the Trichoderma strain via transformation such that a DNA fragment encoding an endoglucanase or derivative thereof is inserted within the genome. It is also contemplated that more than one copy of an endoglucanase DNA fragment or DNA variant fragment may be recombined into the strain.

A selectable marker must first be chosen so as to enable detection of the transformed fungus. Any selectable marker gene which is expressed in Trichoderma can be used in the present invention so that its presence in the transformants will not materially affect the properties thereof. The selectable marker can be a gene which encodes an assayable product. The selectable marker may be a functional copy of a Trichoderma gene which if lacking in the host strain results in the host strain displaying an auxotrophic phenotype.

The host strains used could be derivatives of Trichoderma which lack or have a non-functional gene or genes corresponding to the selectable marker chosen. For example, if the selectable marker of pyr4 is chosen, then a specific pyr derivative strain is used as a recipient in the transformation procedure. Other examples of selectable markers that can be used in the present

invention include the Trichoderma genes equivalent to the Aspergillus nidulans genes argB, trpC, niaD and the like. The corresponding recipient strain must therefore be a derivative strain such as $argB^-$, $trpC^-$, $niaD^-$, and the like.

- 29 -

The strain is derived from a starting host strain which is any *Trichoderma* strain. However, it is preferable to use a *T. longibrachiatum* cellulase over-producing strain such as RL-P37, described by Sheir-Neiss et al. in Appl. Microbiol. Biotechnology, 20 (1984) pp. 46-53, since this strain secretes elevated amounts of cellulase enzymes. This strain is then used to produce the derivative strains used in the transformation process.

The derivative strain of Trichoderma can be prepared by a number of techniques known in the art. An example is the production of pyr4 derivative strains by subjecting the strains to fluoroorotic acid (FOA). The pyr4 gene encodes orotidine-5'-monophosphate decarboxylase, enzyme required for the biosynthesis of uridine. with an intact pyr4 gene grow in a medium lacking uridine but are sensitive to fluoroorotic acid. It is possible to select pyr4 derivative strains which lack a functional orotidine monophosphate decarboxylase enzyme and require uridine for growth by selecting for FOA resistance. Using the FOA selection technique, it is also possible to obtain uridine requiring strains which lack a functional orotate pyrophosphoribosyl transferase. It is possible to transform these cells with a functional copy of the gene encoding this enzyme (Berges and Barreau, 1991, Curr. Genet. 19 pp359-365). Since it is easy to select

- 30 -

derivative strains using the FOA resistance technique in the present invention, it is preferable to use the pyr4 gene as a selectable marker.

In a preferred embodiment of the present invention, Trichoderma host cell strains are deleted of one or more cellobiohydrolase genes prior to introduction of a DNA construct or plasmid containing the DNA fragment encoding the endoglucanase of interest. It is preferable to express an endoglucanase, derivative thereof or covalently linked endoglucanase domain derivative in a host that is missing one or more cellobiohydrolase genes in order to simplify the identification and subsequent purification procedures. Any gene from Trichoderma which has been cloned can be deleted such as cbh1 or cbh2.

The desired gene that is to be deleted from the transformant is inserted into a plasmid by methods known in the art. This plasmid is selected such that unique restriction enzyme sites are present therein to enable the fragment of Trichoderma DNA to be subsequently removed as a single linear piece. The plasmid containing the gene to be deleted or disrupted is then cut at appropriate restriction enzyme site(s), internal to the coding region, the gene coding sequence or part thereof may be removed therefrom and the selectable marker (e.g. pry 4) inserted. Flanking DNA sequences from the locus of the gene to be deleted or disrupted, preferably between about 0.5 to 2.0 kb, remain on either side of the selectable marker gene.

- 31 -

A single DNA fragment containing the deletion construct is then isolated from the plasmid and used to transform the appropriate pyr Trichoderma host. Transformants are selected based on their ability to express the pyr4 gene product and thus complement the uridine auxotrophy of the host strain. Southern blot analysis is then carried out on the resultant transformants to identify and confirm a double cross-over integration event which replaces part or all of the coding region of the gene to be deleted with the pyr4 selectable markers.

Although specific plasmid vectors are described above, the present invention is not limited to the production of these vectors. Various genes can be deleted and replaced in the *Trichoderma* strain using the above techniques. Any available selectable markers can be used, as discussed above. Potentially any *Trichoderma* gene which has been cloned, and thus identified, can be deleted from the genome using the above-described strategy.

The expression vector of the present invention carrying the inserted DNA fragment or variant DNA fragment encoding the endoglucanase or derivative thereof of the present invention may be any vector which is capable of replicating autonomously in a given host organism, typically a plasmid. In preferred embodiments two types of expression vectors for obtaining expression of genes or truncations thereof are contemplated. The first contains DNA sequences in which the promoter, gene coding region, and terminator sequence all originate from the gene to be expressed. Gene truncation if required is obtained by deleting away the undesired DNA sequences

WO 95/16360 PCT/EP94/04212 - 32 -

(coding for unwanted domains) to leave the domain to be expressed under control of its own transcriptional and translational regulatory sequences. A selectable marker is also contained on the vector allowing the selection for integration into the host of multiple copies of the novel gene sequences.

For example, a DNA construct which can be termed pEGID3'pyr contains the EGI cellulase core domain under the control of the EGI promoter, terminator, and signal The sequences. 3 ' end on the EGI coding containing the cellulose binding domain has been deleted. The plasmid also contains the pyr4 gene for the purpose of selection.

The second type of expression vector is preassembled and contains sequences required for high level transcription and a selectable marker. It is contemplated that the coding region for a gene or part thereof can be inserted into this general purpose expression vector such that it is under the transcriptional control of the expression cassette's promoter and terminator sequences.

For example, pTEX is such a general purpose expression vector. Genes or part thereof can be inserted downstream of the strong CBHI promoter.

the vector, the DNA sequence encoding the endoglucanase should be operably linked transcriptional and translational sequences, suitable promoter sequence and signal sequence in reading frame to the structural gene. The promoter may be any

- 33 -

DNA sequence which shows transcriptional activity in the host cell and may be derived from genes encoding proteins either homologous or heterologous to the host cell. The signal peptide provides for extracellular expression of the endoglucanase or derivatives thereof. The DNA signal sequence is preferably the signal sequence naturally associated with the truncated gene to be expressed, however the signal sequence from any endoglucanase is contemplated in the present invention.

The procedures used to ligate the DNA sequences coding for the truncated endoglucanases or derivatives thereof with the promoter, and insertion into suitable vectors containing the necessary information for replication in the host cell are well known in the art.

The DNA vector or construct described above may be introduced in the host cell in accordance with known techniques such as transformation, transfection, microinjection, microporation, biolistic bombardment and the like.

In a preferred embodiment of the present invention, the modified strain is derived from Trichoderma sp. containing deleted or disrupted genes for CBHI and/or CBHII thereby being unable to produce catalytically active cellobiohydrolase. The cellulase enzymes produced by such an organism will be enriched in endoglucanases and include no more than 20% cellobiohydrolases based upon the combined weight of cellulase proteins which it produces. It is particularly preferred that the modified strain is unable to produce catalytically active CBHI as

this enzyme forms the greatest proportion of any component of whole cellulase from *Trichoderma sp*. In instances where only production of EGIII is desired, it is further preferred that such a modified strain contains deleted or disrupted genes for EGI and EGII so as to be unable to produce catalytically active EGI and/or EGII.

Alternatively, the modified strain can additionally contain recombinant DNA allowing expression and secretion of truncated catalytic cores of either EGI or EGII. While not wishing to be bound by theory, it is believed that the presence of a cellulose binding domain on a cellulase may be responsible for certain undesirable properties observed when animals fed feed are supplemented with cellulase, e.g. increased gut viscosity. Accordingly, by removing the cellulose binding domain and retaining an intact cellulase core, it is possible to limit or eliminate these properties.

Before describing methods of producing such truncated endoglucanases, the following provides a detailed description of the drawings which is necessary to understand these production techniques.

Figure 1 depicts the genomic DNA and amino acid sequence of EGI. The signal sequence begins at base pair 113 and ends at base pair 178 (Seq ID No. 13). The catalytic core domain begins at base pair 179 through 882 of exon one, and base pair 963 through base pair 1379 of the second exon (Seq ID No. 5). The linker region begins at base pair 1380 and ends at base pair 1460 (Seq ID No. 9). The cellulose binding domain begins at base pair 1461 and

- 35 -

ends at base pair 1616 (Seq ID No. 1). Seq ID Nos. 14, 6, 10 and 2 represent the amino acid sequence of EGI signal sequence, catalytic core domain, linker region and binding domain, respectively.

Figure 2 depicts the genomic DNA and amino acid sequence of EGII. The signal sequence begins at base pair 262 and ends at base pair 324 (Seq ID No. 15). The cellulose binding domain begins at base pair 325 and ends at base pair 432 (Seq ID No. 3). The linker region begins at base pair 433 and ends at base pair 534 (Seq No. 11). The catalytic core domain begins at base pair 535 through base pair 590 in exon one, and base pair 765 through base pair 1689 in exon two (Seq ID No. 7). Seq ID Nos. 16, 4, 12 and 8 represent the amino acid sequence of EGII signal sequence, binding domain, linker region and catalytic core domain, respectively.

Figure 3 depicts the genomic DNA and amino acid sequence of EGIII. The signal sequence begins at base pair 151 and ends at base pair 198 (Seq ID No. 19). The catalytic core domain begins at base pair 199 through base pair 557 in exon one, base pair 613 through base pair 833 in exon two and base pair 900 through base pair 973 in exon three (Seq ID No. 17). Seq ID Nos. 20 and 18 represent the amino acid sequence of EGIII signal sequence and catalytic core domain, respectively.

Figure 4 illustrates the construction of EGI core domain expression vector (Seq ID No. 21).

Figure 5 is a graph demonstrating the initial viscosity-reducing activity of whole cellulase and various enriched endoglucanase preparations at different pHs.

- 36 -

As mentioned above, the one or more endoglucanases present in the enzyme feed additive of the present invention may be truncated EG derivatives such as EGI which lacks the cellulose binding domain (which can be termed EGIcore) and/or EGII also lacking the cellulose These derivatives are prepared by binding domain. recombinant methods by transforming into a host cell, a DNA construct comprising at least a fragment of DNA encoding a portion or all of the core region of the endoglucanases, for example, EGI or EGII functionally attached to a promoter, growing the host cell to express the truncated endoglucanase, derivative of truncated covalently endoglucanase or linked truncated endoglucanase domain derivatives of interest. The resulting truncated endoglucanase can be used once separated from the microrganism cells as a feed additive. an alternative, the truncated endoglucanase, derivative thereof may in addition be purified to substantial homogeneity prior to use.

The following Reference Examples 1 and 2 are provided in order to illustrate techniques for producing endoglucanase enriched enzyme compositions by transforming and growing genetically modified microorganisms.

- 37 **-**

Reference Example 1.

Cloning and Expression of EG1 Core Domain Using its Own Promoter, Terminator and Signal Sequence.

Part 1. Cloning.

The complete egl1 gene used in the construction of the EG1 core domain expression plasmid, pEG1D3'pyr, was obtained from the plasmid pUC218::EG1. (See FIG.4.) terminator region of egl was ligated into pUC218 (Korman, D. et al Curr Genet 17:203-212, 1990) as a 300 bp BsmI-EcoRI fragment (the BsmI site is at 46 bp 3' of the eql1 stop codon) along with a synthetic linker designed to replace and cellulose binding domain of egl with a stop codon and continue with the first 46 bp of the eql1 terminator sequence. The resultant plasmid, pEG1T, was digested with HindIII and BsmI and the vector fragment with the egll terminator was isolated from the digest by agarose gel electrophoresis followed by electroelution. The egl1 gene promoter sequence and core domain of egl1 were isolated from pUC218::EG1 as a 2.3kb HindIII-SstI fragment and ligated with the same synthetic linker fragment and the HindIII-BsmI digested pEG1T to form pEG1D3'

The net result of these operations is to replace the 3' intron and cellulose binding domain of egl1 with synthetic oligonucleotides of 53 and 55nt. These place a TAG stop

codon after serine 415 and thereafter continued with the egl1 terminator up to the BsmI site.

- 38 -

Next, the *T. longibrachiatum* selectable marker, *pyr4*, was obtained from a previous clone p219M (Smith et al 1991), as an isolated 1.6kb *EcoRI-HindIII* fragment. This was incorporated into the final expression plasmid, pEG1D3'pyr, in a three way ligation with pUC18 plasmid digested with *EcoRI* and dephosphorylated using calf alkaline phosphatase and a *HindIII-EcoRI* fragment containing the *egl1* core domain from pEG1D3'.

Part 2. Transformation and Expression.

A large scale DNA prep was made of pEG1D3'pyr and from this the *EcoRI* fragment containing the egl1 core domain and *pyr4* gene was isolated by preparative gel electrophoresis. The isolated fragment was transformed into a strain (1A52pyr13) in which the cbh1, cbh2, egl1 and egl2 genes had been deleted and which was pyr4 (described in WO 92/06209) and stable transformants were identified.

To select which transformants expressed egll core domain the transformants were grown up in shake flasks under conditions that favored induction of the cellulase genes (Vogel's medium + 1% lactose). After 4-5 days of growth, protein from the supernatants was concentrated and either 1) run on SDS polyacrylamide gels prior to detection of the EGI core domain by Western analysis using anti-EGI polyclonal antibodies or 2) the concentrated supernatants

- 39 -

were assayed directly using Remazol Brilliant Blue (RBB) carboxy methyl cellulose as an endoglucanase specific substrate and the results compared to the parental strain (1A52) as a control. Transformant candidates were identified as possibly producing a truncated EGI core domain protein. Genomic DNA and total mRNA was isolated from these strains following growth on Vogels + Southern and Northern blot experiments lactose and performed using an isolated DNA fragment containing only the egl1 core domain. These experiments demonstrated that transformants could be isolated having a copy of the egl1 core domain expression cassette integrated into genome of 1A52 and that these same transformants produced egl1 core domain mRNA.

One transformant was then grown using media suitable for cellulase production in Trichoderma well known in the art that was supplemented with lactose (Warzymoda, M. et al 1984 French Patent No. 2555603) in a 14L fermentor. broth was concentrated and the contained therein were separated by SDS polyacrylamide gel electrophoresis and the EGI core domain protein identified by Western analysis. It was subsequently estimated that the protein concentration of fermentation supernatant was about 5-6 g/L of which approximately 1.7-4.4g/L was EGI core domain based on CMCase activity. This value is based on an average of several EGI core fermentations that were performed.

In a similar manner, any other endoglucanase whether truncated or not or derivative thereof may be produced by

- 40 -

procedures similar to those discussed above. Thus production of EGI can be achieved by using similar techniques except that deletion of the cellulose binding domain is omitted. Corresponding techniques can be used to produce complete EGII, EGIII, and EGII from which the cellulose binding domain is omitted.

Reference Example 2.

Purification of EGI and EGII catalytic cores

Part 1. EGI catalytic core

The EGI core was purified in the following manner. The concentrated (UF) broth was diluted to 14 mg/ml in 23 mM $\,$ Na Acetate pH 5.0. Two hundred grams of avicel cellulose gel (FMC Bioproducts, Type PH-101) was added to the diluted EGI core broth and mixed at room temperature for forty five minutes. The avicel was removed from the broth by centrifugation, resulting in an enriched EGI core solution. This solution was then buffer exchanged into 10 mM TES pH 7.5 using an Amicon stirred cell concentrator with a PM 10 membrane (diaflo ultra filtration membranes, Amicon Cat # 13132MEM 5468A). EGI core sample was then loaded onto an anion exchange column (Q-sepharose fast flow, Pharmacia Cat # 17-0510-01) and eluted in a salt gradient from 0 to 0.5M NaCl in 10 mM TES pH 7.5. The fractions which contained the EGI core were combined and concentrated using the Amicon stirred cell concentrator mentioned above.

Part 2. EGII catalytic core

- 41 -

It is contemplated that the purification of the EGII catalytic core is similar to that of EGII cellulase because of its similar biochemical properties. theoretical pI of the EGII core is less than a half a pH unit lower than that of EGII. Also, EGII core is approximately 80% of the molecular weight of Therefore, the following purification protocol is based on the purification of EGII. The method may involve filtering the UF concentrated broth through diatomaceous earth and adding (NH4)2S04 to bring the solution to 1M This solution may then be loaded onto a (NH4)2S04. hydrophobic column (phenyl-sepharose fast flow, Pharmacia, cat #17-0965-02) and the EGII may be step eluted with 0.15 M (NH4)2S04. The fractions containing the EGII core may then be buffer exchanged into citratephosphate pH 7, 0.18 m0hm. This material may then be loaded onto a anion exchange column (Q-sepharose fast flow, Pharmacia, cat. #17-0510-01) equilibrated in the above citrate-phosphate buffer. It is expected that EGII core will not bind to the column and thus be collected in the flow through.

The present invention will be explained in more detail by way of the following further Reference Example 3 and Example 1. In the Example 1, reference is made to units of β -glucanase activity. This activity is measured by the following assay.

One unit of β -glucanase activity is the amount of enzyme which liberates one μ mol of reducing sugars (expressed as

glucose equivalents) from the substrate in one minute under the conditions described.

Reagents 1. 1.0% (w/v) β -glucan substrate

Moisten 1.0 g of mixed-linked β-(1,3)(1,4)-glucan (Biocon Biochemicals Ltd.) with 10 ml of ethanol. Add about 80 ml of distilled water and warm up to boil. Continue boiling with vigorous stirring until β -glucan is dissolved and a turbid solution is obtained. Cool the turbid solution to room temperature continuously stirring and adjust the β glucan concentration to 1.0% (w/w) by adding distilled water. Filter through a glass fibre filter paper.

The substrate can be used immediately. The substrate is usable for two days if stored in a cold room.

- 2. 0.1 M sodium acetate buffer, pH 5.0
- A. Dissolve 8.2 g of anhydrous sodium acetate in distilled water and fill to 1000 ml with distilled water.
- B. Dissolve 6.0 g of glacial acetic acid in distilled water and fill to 1000 ml with distilled water.

Adjust the pH of solution A to 5.0 with solution B.

3. Dinitrosalicylic acid (DNS) reagent

- 43 -

Suspend 20.0 g of 3,5-dinitrosalicylic acid in about 800 ml of distilled water. Add gradually 300 ml of sodium hydroxide solution (32.0 g of NaOH in 300 ml of distilled water) while stirring continuously. Warm the suspension in a water bath (the temperature may exceed +48°C) while stirring until the solution is clear. Add gradually 600 g of potassium sodium tartrate. Warm the solution (the temperature may not exceed +48°C) if needed until solution is clear.

Fill to 2000 ml with distilled water and filter through a coarse sintered glass filter.

Store in a dark bottle at room temperature. The reagent is stable for a maximum of 6 months.

Procedure 1. Enzyme sample

Equilibrate 1 ml of enzyme dilution (in 0.1 M sodium acetate buffer, pH 5.0) at $+30^{\circ}$ C. Add 1 ml of β -glucan substrate, stir and incubate at $+30^{\circ}$ C for exactly 10

- 44 -

minutes. Add 3 ml of DNS-reagent, stir and boil the reaction mixture for exactly 5 minutes. Cool the reaction mixture in a cold water bath to room temperature and measure the absorbance at 540 nm against distilled water.

2. Enzyme blank

Incubate 1 ml of β -glucan substrate at +30°C for 10 minutes. Add 3 ml of DNS-solution and stir. Add 1 ml of enzyme dilution (in 0.1 M sodium acetate buffer, pH 5.0) and stir. Boil the mixture for exactly 5 minutes. Cool the reaction mixture in cold water bath to room temperature and measure the absorbance at 540 nm against distilled water.

The absorbance difference between the enzyme sample and the enzyme blank should be 0.3-0.5.

3. Standard curve

Prepare standard solutions from anhydrous glucose in distilled water. Glucose concentration in the standards should be 0.1-0.6 mg/ml. Pipette 1 ml of glucose standard solution, 1 ml of distilled water and 3 ml of DNS-reagent into a test tube. Stir and boil for exactly 5

minutes. Cool in a cold water bath to room temperature and measure the absorbance at 540 nm against standard blank. In the standard blank, glucose solution is replaced by 1 ml of distilled water. Otherwise standard blank is treated like glucose standard.

Plot glucose concentration as a function of absorbance. New standard curve is prepared for every new DNS-reagent.

Calculation The β -glucanase activity of the sample is calculated according to the following equation:

Activity $(U/g) = ([A(X) - A(0)] \times k + C_{\underline{\cdot}}) \times 1000 \times Df$ $MW_{glu} \times t$

wherein:

A(X) = absorbance of the enzyme sample
A(O) = absorbance of the enzyme blank
k = the slope of the standard curve

C. = the intercept of glucose standard curve

1000 = factor, mmol -> μ mol Df = dilution factor (ml/g)

 $MW_{glu} = molecular weight of glucose(180.16 mg/mmol)$

t = reaction time (10 minutes)

The Reference Example 3 makes reference to the measurement of the viscosity reducing activity of $\beta\text{--}$

- 46 -

glucanase. This activity is measured by the following assay.

Principle β -glucanase catalyses the hydrolysis of β -glucan which results in reduction of viscosity of β -glucan solution. Reciprocal specific viscosity as a function of time is linear function at the initial moment of the reaction. Using the slope of the linear curve β -glucanase activity can be determined. Reciprocal specific viscosity is determined using a capillary viscosimeter.

Apparatus Ostwald capillary viscosimeter (Brand, No 11, 75-100 sec)

Water bath controlled at 30 °C
Magnetic stirrer
Stop Watch
Glassinter filters no 3 and 4
Magnetic stirrer with hotplate

Reagents 1. 0.5 M acetate buffer, pH 4.0

Dilute 30 g of glacial acetic acid (BDH AnalaR 10001) into 900 ml of distilled water. Adjust the pH to 4.0 with 2.5 g of NaOH (Merck 6498). Fill with distilled water into 1000 ml.

- 47 -

2. 0.05 M acetate buffer, pH 4.0

Dilute 100 ml of 0.5 M acetate buffer, pH 4.0 into 800 ml of distilled water. Adust pH if needed to 4.0 with 1 M NaOH or glacial acetic acid. Fill to 1000 ml with distilled water. Filtrate through glassinter filter no 4.

3. β -glucan solution

Weigh 1.0 g mixed-linked β -(1,3)(1,4)-glucan (Biocon Biochemicals) in a tared beaker. approx. 6 ml of ethanol and mix with metallic mixing rod until the mixed-linked β -glucan has become totally wet. Add approx. 80 ml of distilled water, mix with magnetic stirrer and warm up solution to boil. Keep boiling until the mixed-linked β -glucan has totally Ensure that there is no material dissolved. on the walls of the beaker. Cool the solution to room temperature while continuously stirring. Add 10 ml of 0.5 M acetate buffer, pH 4.0. If needed adjust pH to 4.0 with 1 M NaOH or glacial acetic acid. Add distilled water until the total weight of the substrate solution is 100 g. Filtrate with glassinter filter no 3. Store the substrate solution maximum for two days at +4 °C.

- 48 -

Procedure 1. Determination of reciprocal specific viscosity

Before activity determination ensure that viscosimeter is clean by rinsing with distilled water and acetone (in this sequence). Dry the viscosimeter by removing acetone with compressed air or in vacuum.

All samples, substrate solution and viscosimeter have to be equilibrated at 30 °C for at least 15 minutes before determination.

Reciprocal specific viscosity follows equation 1

$$dT_0$$

$$1/\mu_{sp} = -------- (Equation 1)$$

$$dT_s - dT_0$$

whereas

 $1/\mu_{sp}$ = reciprocal specific viscosity

 dT_0 = falling-time of acetate buffer (in

seconds)

 dT_s = falling-time of sample solution (in

seconds)

The falling-time for solutions follow equation 2

 $dT_i = T_2 - T_1 - h$ (Equation 2)

where

 dT_i = falling-time of solutions

 $T_2 - T_1 =$ time used by the solution to fall between upper and

lower marks in the

capillary (in seconds)

h = Hagenbach factor

- 49 -

Hagenbach factors:

Falli	ng s	-time	(dT_i)	h
				· · · · · · · · · · · · · · · · · · ·
	<	54.2		1.0
54.3	-	57.3		0.9
57.4	-	60.5		0.8
60.6	-	65.5		0.7
65.6	-	70.8		0.6
70.9	-	78.5		0.5
78.6	-	88.9		0.4
89.0	-	105		0.3
105	_	135		0.2
135	-	240		0.1
	>	240		0

Start the determination of the falling-time with a clean and dry viscosimeter by pumping 7.5 ml of solution to the capillary so that the surface of the solution exceeds the upper mark of the capillary. Determine with stop watch the time needed for the solution to fall between upper and lower marks in the capillary.

2. Determination of falling-time for acetate buffer

Determine the falling-time (dT_0) for 0.05 M acetate buffer, pH 4.0, as described above whenever β -glucanase activity is determined.

3. Adjustment of β -glucan solution

- 50 -

The initial reciprocal specific viscosity in the hydrolysis of β -glucan has to be 0.13. The viscosity in the β -glucan solution varies from batch to batch and this has to be compensated by varying the ratio of β -glucan solution and sample so that the initial viscosity is correct.

Make 5 different β -glucan/0.05 M acetate buffer, pH 4.0, mixtures by pipetting β -glucan (A) 5.0-6.5 ml and respectively 2.5-1.0 ml of 0.05 M acetate buffer, pH 4.0, to make the total volume of each mixture to be 7.5 ml. Determine the viscosities of these solutions and calculate the reciprocal specific viscosities.

Plot the reciprocal specific viscosity as a β -glucan. function οf From the graph determine the amount of β-glucan that corresponds to a reciprocal specific viscosity value of 0.13. This β -glucan amount will be used later on in all β -glucanase activity determinations with this β -glucan solution.

Initial viscosity of β -glucan solution has to be determined whenever β -glucanase activity is determined.

- 51 -

4. Determination of β -glucanase activity

Pipette β -glucan volume (A) determined as described above to the test tube equilibrate at 30 °C for at least 15 minutes. Add V ml (V = 7.5 ml - A) of enzyme sample diluted in 0.05 M acetate buffer, pH 4.0 and equilibrated at 30 °C for at least 15 minutes. Start the stop watch. Mix the solution properly and transfer it to the viscosimeter. Determine falling-time dT_s 4-5 times during from the 20-30 minutes mixing of solutions.

The determinations have to be done from at least two different dilutions and with at least 3 parallel determinations from each dilution. Proper dilution of the sample depends on enzyme mixture product and end feed to be assayed. The dilutions indicated separately. For enzyme mixtures the total dilution factor is typically 1/2000-1/15000 and for end feeds 1/5-1/20.

Calculations Calculate the reciprocal specific viscosities according to equation 1. Plot the reciprocal specific viscosity as a function of hydrolysis time (in seconds).

WO 95/16360 - 52 -

PCT/EP94/04212

 β -glucanase activity is determined as an increase of reciprocal specific viscosity (IRV) in one minute, equation 3.

 $\beta\text{-glucanase activity (IRVU/g)} = \begin{cases} k \times D \times 60 \\ ----- \text{(Equation 3)} \\ v \end{cases}$ where

k = slope of the curve
D = total dilution factor

60 = conversion factor, s -> min

V = sample volume

Literature The Institute of Brewing (1979) J. Inst. Brew, 85, 92-94.

Analyse av β -glukanaseaktivitet ved viskosimetrisk metode, Norges Veterinaerhogskole.

Reference Example 3

The first trial which was undertaken was to compare the efficacy in vitro of several different cellulases having an enriched content of endoglucanases in comparison with whole cellulase. Thus, seven different enzyme preparations were prepared the first from naturally occurring T. longibrachiatum and the second-seventh from genetically modified strains thereof in accordance with the following Table 1:

- 53 -

Table 1

Enzyme Preparation	Strain Genotype
Whole cellulase	EGI, EGII, EGIII, CEHI, CHBII,
Enriched EGI	EGI*** EGII* EGIII* CBHI CHBII
Enriched EGI.Acbd	EGI.Acbd' EGI' EGII' EGIII' CBHI' CBHII'
Enriched EGII	EGI. EGII EGIII. CEHI. CBHII.
Enriched EGIII	EGI, EGII, EGIII, CBHI, CBHII,
Purified EGIII	EGI, EGII, EGIII, CEHI, CEHII,

In the above Table 1, the strain producing enriched EGI contains multiple EGI encoding genes. Similarly, the strains producing enriched EGII and EGIII respectively contain multiple copies of the EGII and EGIII encoding genes.

The enriched EGI, enriched EGII, enriched EGIII and purified EGIII enzyme preparations were obtained by following the procedures described in PCT WO 92/06209. Purified EGIII was the same as enriched EGIII, except that the supernatant containing the secreted EGIII was subjected to the PEG purification procedure described in U.S. Patent No. 5,328,841 to remove xylanase activity. Truncated EGI core was produced according to the techniques described in Reference Example 1 and purified in accordance with Reference Example 2.

The viscosity reducing activity on soluble mixed-linked barley β -glucan was measured for each of the above enzyme

preparations in accordance with the assay described above.

The results of this testing are illustrated in the graph of Figure 5. Since T. longibrachiatum β -glucanase is dosed as a feed additive on the basis of activity measured by the DNS reducing sugar assay method, enzyme addition for the viscosity-reducing activity assay was standardised by this procedure.

The results illustrated in Figure 5 demonstrate that the viscosity-reducing activity of whole cellulase is significantly higher than that of each of the enriched endoglucanese preparations regardless of pH.

Example 1

Thirteen groups of broiler chickens, each initially including a minimum of 49 chickens, were fed with the barley-based feed set out in Table 2 between 8 and 21 days of age. Feed intake and body weight gain were measured between 8 and 21 days.

Table 2

Ingredients	Percent	Weight	
Barley	58.56%	585.63	
Soybean ml 48	31.63%	316.26	
Soy oil	6.07%	60.65	
Salt	0.29%	2.90	
DL Methionine	0.28%	2.76	
Lysine HCl	0.04%	0.44	
Limestone	1.41%	14.06	
Dicalcium Phos	1.23%	12.31	
VIT/MIN	0.50%	5.00	
TOTAL	100.00%	1000.00	

The nutritional value of the above feed can be subjected to computer analysis using for example the programme "Format" available from Format International. This provides an analysis of the nutrient content of the feed including for example the expected nutritional levels of various metabolites. The results of such an analysis for the feed of Table 2 is set out in the following Table 3.

Barley-Based Diet
TABLE 3

Nutrient	Target	Value
Crude protein %	22.00	22.00
Poult ME kcal/kg	3000.00	3000.00
Pig DE Kcal		3363.16
Calcium %	0.90	0.90
Phos %		0.66
Avail Phos %	0.40	0.40
Fat %		7.28
Fibre %		4.00
Met %		0.58
Cys %		0.37
Met + Cys %	0.95	0.95
Lys %	1.25	1.25
His %		0.52
Tryp %	0.24	0.30
Thr %	0.80	0.82
Arg %	1.40	1.44
Iso %		1.01
Leu %		1.59
Phe %		1.11
Val %		1.10
Gly %		0.99
Phe + Tyr %		1.89
Na %	0.15	0.15
Cl %		0.29
K %		0.96
Linoleic acid %	1.00	3.00
Na + K + HCl		2.29

The barley-based feeds fed to twelve of the groups of chickens were supplemented by varying amounts of each of

the enzyme preparations set out in the above Table 1. Each of the enzyme preparations was tested at a β -glucanase activity concentration of 120 units/kg of the feed and 240 units/kg of the feed. The β -glucanase activity was measured using the β -glucanase activity assay described above. The diet of the thirteenth group, the control group, was not supplemented with any of the enzyme preparations.

Results of these various tests are set out in the following Tables 4 and 5. The results set out in Table 4 are for diets supplemented with 120 units of β -glucanase activity per kg of feed whereas the results set out in Table 5 are for feeds supplemented with 240 units of β -glucanase activity per kg of feed. The results set out in the Tables 4 and 5 provide the body weight gain, the feed conversion ratio and the viscosity in the gastrointestinal region of the various groups of broiler chickens. The results have been adjusted for mortality.

Table 4

	BWG(g)	FCR	Viscosity (cps)
Control	329	1.72	15.3
Enriched EGI	358	1.60	12.6
Enriched EGI.Δcbd	437	1.42	10.5
Enriched EGII	396	1.50	13.6
Enriched EGIII	356	1.66	6.0
Purified EGIII	332	1.85	7.9
Complete Cellulase	381	1.62	10.3

- 57 -

Table 5

BWG(g)	FCR	Viscosity (cps)	
329	1.72	15.3	
376	1.60	14.5	
395	1.57	5.6	
377	1.70	11.6	
423	1.54	8.1	
401	1.56	7.7	
404	1.66	6.4	
	329 376 395 377 423	329 1.72 376 1.60 395 1.57 377 1.70 423 1.54 401 1.56	329 1.72 15.3 376 1.60 14.5 395 1.57 5.6 377 1.70 11.6 423 1.54 8.1 401 1.56 7.7

From the above results, it can be seen that the body weight gain, feed conversion ratio and viscosity for the control group without enzyme supplementation relatively poor. In comparison with the results for whole cellulase, enriched EGI is more effective in terms of FCR when used at a dosage of 240 units/kg of feed. The same is also true for enriched EGIII and purified EGIII. On the other hand, enriched EGII provides superior results at 120 units/kg of feed. Finally, the most preferred enzyme preparation, which is the enriched EGI. Δ cbd provides superior results at both 120 and 240 units/kg of feed. This enzyme preparation deleted for the cellulose binding domain provides superior results at both concentrations tested as compared to enriched natural type EGI. These results also strongly suggest that the different enzyme preparations have different dose optima in terms of their effects on body weight gain and feed conversion ratios.

By comparing the results of Reference Example 3 and Example 1, it can be seen that different results are obtained between in vitro and in vivo testing. Thus, in

the *in vitro* testing of Reference Example 3, the viscosity reducing activity of whole cellulase was higher than that for the enriched preparations of EGI, EGII, EGIII and EGI. Δcbd .

- 58 -

In contrast, the *in vivo* test results of Example 1 indicate that each of the enzyme preparations tested has at least one advantageous characteristic of improved body weight gain, feed conversion ratio and/or reduced viscosity in the gastrointestinal region as compared to whole cellulase at both concentrations tested. The preferred enzyme preparations are EGI. Acbd and EGIII.

The effects demonstrated above of reducing feed conversion ratios and/or gastrointestinal viscosities can also be obtained when feeds prepared in accordance with the present invention but based upon other cereals such as wheat, triticale, rye and maize are fed to other animals such as turkeys, geese, ducks, pigs, sheep and cattle, as well as chickens.

- 59 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (2) INFORMATION FOR SEQ ID NO:1:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 159 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: join(1..82, 140..159)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAC TGG GGG CAG TGC GGT GGC ATT GGG TAC AGC GGG TGC AAG ACG TGC

48

His Trp Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Cys Lys Thr Cys

1 5 10 15

- 60 -

ACG TCG GGC ACT ACG TGC CAG TAT AGC AAC GAC T GTTCGTATCC 92

Thr Ser Gly Thr Thr Cys Gln Tyr Ser Asn Asp

CCATGCCTGA CGGGAGTGAT TTTGAGATGC TAACCGCTAA AATACAG AC TAC TCG 147

Tyr Tyr Ser

30

CAA TGC CTT TA

Gln Cys Leu

(2) INFORMATION FOR SEQ ID NO:2:

20

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

His Trp Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Cys Lys Thr Cys

1 5 10 15

Thr Ser Gly Thr Thr Cys Gln Tyr Ser Asn Asp Tyr Tyr Ser Gln Cys
20 25 30

Leu

- (2) INFORMATION FOR SEQ ID NO:3:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 108 base pairs
 - (B) TYPE: nucleic acid

- 61 -

(C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..108 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: CAG CAG ACT GTC TGG GGC CAG TGT GGA GGT ATT GGT TGG AGC GGA CCT 48 Gln Gln Thr Val Trp Gly Gln Cys Gly Gly Ile Gly Trp Ser Gly Pro 1 10 15 ACG AAT TGT GCT CCT GGC TCA GCT TGT TCG ACC CTC AAT CCT TAT TAT 96 Thr Asn Cys Ala Pro Gly Ser Ala Cys Ser Thr Leu Asn Pro Tyr Tyr 20 25 30 GCG CAA TGT ATT 108 Ala Gln Cys Ile 35 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gln Gln Thr Val Trp Gly Gln Cys Gly Gly Ile Gly Trp Ser Gly Pro

1 10 15

- 62 -

Thr Asn Cys Ala Pro Gly Ser Ala Cys Ser Thr Leu Asn Pro Tyr Tyr

20 25 30

Ala Gln Cys Ile

35

- (2) INFORMATION FOR SEQ ID NO:5:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1201 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: join(1..704, 775..1201)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CAG CAA CCG GGT ACC AGC ACC CCC GAG GTC CAT CCC AAG TTG ACA ACC

48
Gln Gln Pro Gly Thr Ser Thr Pro Glu Val His Pro Lys Leu Thr Thr

1 5 10 15

TAC AAG TGT ACA AAG TCC GGG GGG TGC GTG GCC CAG GAC ACC TCG GTG 96

Tyr Lys Cys Thr Lys Ser Gly Gly Cys Val Ala Gln Asp Thr Ser Val

20 25 30

GTC CTT GAC TGG AAC TAC CGC TGG ATG CAC GAC GCA AAC TAC AAC TCG

144

Val Leu Asp Trp Asn Tyr Arg Trp Met His Asp Ala Asn Tyr Asn Ser

35

40

45

TGC ACC GTC AAC GGC GGC GTC AAC ACC ACG CTC TGC CCT GAC GAG GCG 192

- 63 -

Cys	Thr	Val	Asn	Gly	GIY	Val	Asn	Thr	Thr	Leu	Cys	Pro	Asp	Glu	Ala	
	50					55					60					
ACC	TGT	GGC	AAG	AAC	TGC	TTC	ATC	GAG	GGC	GTC	GAC	TAC	GCC	GCC	TCG	240
Thr	Cys	Gly	Lys	Asn	Cys	Phe	Ile	Glu	Gly	Val	Asp	Tyr	Ala	Ala	Ser	
65					70					75					80	
GGC	GTC	ACG	ACC	TCG	GGC	AGC	AGC	CTC	ACC	ATG	AAC	CAG	TAC	ATG	CCC	288
Gly	Val	Thr	Thr	Ser	Gly	Ser	Ser	Leu	Thr	Met	Asn	Gln	Tyr	Met	Pro	
				85					90					95		
AGC	AGC	TCT	GGC	GGC	TAC	AGC	AGC	GTC	TCT	CCT	CGG	CTG	TAT	CTC	CTG	336
Ser	Ser	Ser	Gly	Gly	Tyr	Ser	Ser	Val	Ser	Pro	Arg	Leu	Tyr	Leu	Leu	
			100					105					110			
GAC	TCT	GAC	GGT	GAG	TAC	GTG	ATG	CTG	AAG	CTC	AAC	GGC	CAG	GAG	CTG	384
Asp	Ser	Asp	Gly	Glu	Tyr	Val	Met	Leu	Lys	Leu	Asn	Gly	Gln	Glu	Leu	
		115					120					125				
AGC	TTC	GAC	GTC	GAC	CTC	TCT	GCT	CTG	CCG	TGT	GGA	GAG	AAC	GGC	TCG	432
Ser	Phe	Asp	Val	Asp	Leu	Ser	Ala	Leu	Pro	Cys	Gly	Glu	Asn	Gly	Ser	
	130					135					140					
CTC	TAC	CTG	TCT	CAG	ATG	GAC	GAG	AAC	GGG	GGC	GCC	AAC	CAG	TAT	AAC	480
Leu	Tyr	Leu	Ser	Gln	Met	Asp	Glu	Asn	Gly	Gly	Ala	Asn	Gln	Tyr	Asn	
145					150					155					160	
ACG	GCC	GGT	GCC	AAC	TAC	GGG	AGC	GGC	TAC	TGC	GAT	GCT	CAG	TGC	ccc	528
Thr	Ala	Gly	Ala	Asn	Tyr	Gly	Ser	Gly	Tyr	Cys	Asp	Ala	Gln	Cys	Pro	

WO 95/16360	PCT/EP94/04212

- 64 -

	CAG	ACA	TGG	AGG	AAC	GGC	ACC	CTC	AAC	ACT	AGC	CAC	CAG	GGC	TTC	576
Val	Gln	Thr	Trp	Arg	Asn	Gly	Thr	Leu	Asn	Thr	Ser	His	Gln	Gly	Phe	
			180					185					190			
TGC	TGC	AAC	GAG	ATG	GAT	ATC	CTG	GAG	GGC	AAC	TCG	AGG	GCG	AAT	GCC	624
Cys	Cys	Asn	Glu	Met	Asp	Ile	Leu	Glu	Gly	Asn	Ser	Arg	Ala	Asn	Ala	
		195					200					205				
																,
TTG	ACC	CCT	CAC	TCT	TGC	ACG	GCC	ACG	GCC	TGC	GAC	TCT	GCC	GGT	TGC	672
Leu	Thr	Pro	His	Ser	Cys	Thr	Ala	Thr	Ala	Cys	Asp	Ser	Ala	Gly	Cys	
	210					215					220					
GGC	TTC	AAC	CCC	TAT	GGC	AGC	GGC	TAC	AAA	AG	GTG	AGCC	TGA			714
Gly	Phe	Asn	Pro	Tyr	Gly	Ser	Gly	Tyr	Lys	Ser	•					
225					230					235	;					
TGCC	CACTA	ACT F	ACCCC	TTTC	C TO	GCGC	TCTC	GCG	GTTI	TCC	ATGC	TGAC	AT G	GTTI	TCCAG	774
C TA	C TA	C GG	sc cc	C GG	SA GA	T AC	C GI	TT GA	C AC	C TC	C AA	G AC	C TI	C AC	:C	820
			SC CC													820
					y As					ır Se					ır	820
				o Gl	y As				sp Th	ır Se				e Th	ır	820
Ту	r T)	r Gl		0 Gl 24	y As	p Th	nr Va	al As	sp Th	ır Se	r Ly	rs Th	r Ph	e Th	ar 50	820
T _y	Yr Ty	r Gl	ly Pr	TTC	y As	p Th	nr Va	al As	EP Th	ar Se	r Ly	rs Th	r Ph	e Th	OTT	
T _y	Yr Ty	r Gl	y Pr	TTC	y As	p Th	nr Va	al As	EP Th	ar Se	r Ly	rs Th	r Ph	e Th	OTT	
T _y	Yr Ty	r Gl	y Pr	TTC	y As	p Th	nr Va	al As	24 GGC	ar Se	r Ly	rs Th	r Ph	e Th 25 AAC Asn	OTT	
Ty ATC	ATC	ACC	y Pr	TTC Phe	.y As 10 AAC Asn	ACG	ar Va GAC Asp	al As AAC Asn	GGC Gly 260	r Se 15 TCG Ser	ccc Pro	TCG	ggc Gly	AAC Asn 265	or CTT Leu	
Ty ATC	ATC	ACC Thr	CAG Gln ACC	TTC Phe 255	AAC ASN	ACG Thr	GAC Asp	AAC Asn	GGC Gly 260	TCG Ser	CCC Pro	TCG Ser	GGC Gly	AAC ASN 265	CTT Leu	868

- 65 -

GCC CAG CCC GGC GGC GAC ACC ATC TCG TCC TGC CCG TCC GCC TCA GCC 964 Ala Gln Pro Gly Gly Asp Thr Ile Ser Ser Cys Pro Ser Ala Ser Ala 285 290 295 TAC GGC GGC CTC GCC ACC ATG GGC AAG GCC CTG AGC AGC GGC ATG GTG 1012 Tyr Gly Gly Leu Ala Thr Met Gly Lys Ala Leu Ser Ser Gly Met Val 305 300 310 CTC GTG TTC AGC ATT TGG AAC GAC AGC CAG TAC ATG AAC TGG CTC 1060 Leu Val Phe Ser Ile Trp Asn Asp Asn Ser Gln Tyr Met Asn Trp Leu 315 320 325 330 GAC AGC GGC AAC GCC GGC CCC TGC AGC AGC ACC GAG GGC AAC CCA TCC 1108 Asp Ser Gly Asn Ala Gly Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser 335 340 345 AAC ATC CTG GCC AAC AAC CCC AAC ACG CAC GTC GTC TTC TCC AAC ATC 1156 Asn Ile Leu Ala Asn Asn Pro Asn Thr His Val Val Phe Ser Asn Ile 3.5 C 355 360 CGC TGG GGA GAC ATT GGG TCT ACT ACG AAC TCG ACT GCG CCC CCG 1201 Arg Trp Gly Asp Ile Gly Ser Thr Thr Asn Ser Thr Ala Pro Pro

(2) INFORMATION FOR SEQ ID NO:6:

365

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 377 amino acids

370

375

- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

- 66 -

PCT/EP94/04212

(ii) M(DLECULE	TYPE:	protein
---------	---------	-------	---------

WO 95/16360

(xi) SI	OUENCE	DESCRIPTION:	SEO	ID	NO:6:
---------	--------	--------------	-----	----	-------

Gln	Gln	Pro	Gly	Thr	Ser	Thr	Pro	Glu	Val	His	Pro	Lys	Leu	Thr	Thr
1				5					10					15	
Tyr	Lys	Cys	Thr	Lys	Ser	Gly	Gly	Cys	Val	Ala	Gln	Asp	Thr	Ser	Val
			20					25					30		
Val	Leu	Asp	Trp	Asn	Tyr	Arg	Trp	Met	His	Asp	Ala	Asn	Tyr	Asn	Ser
		35					40					45			
Cys	Thr	Val	Asn	Gly	Gly	Val	Asn	Thr	Thr	Leu	Cys	Pro	Asp	Glu	Ala
	50					55					60				
Thr	Cys	Gly	Lys	Asn	Cys	Phe	Ile	Glu	Gly	Val	Asp	Tyr	Ala	Ala	Ser
65					70					75					80
Gly	Val	Thr	Thr	Ser	Gly	Ser	Ser	Leu	Thr	Met	Asn	Gln	Tyr	Met	Pro
				85					90					95	
Ser	Ser	Ser	Gly	Gly	Tyr	Ser	Ser	Val	Ser	Pro	Arg	Leu	Tyr	Leu	Leu
			100					105					110		
Asp	Ser	Asp	Gly	Glu	Tyr	Val	Met	Leu	Lys	Leu	Asn	Gly	Gln	Glu	Leu
		115					120					125			
Ser	Phe	Asp	Val	Asp	Leu	Ser	Ala	Leu	Pro	Cys	Gly	Glu	Asn	Gly	Ser
	130					135					140				
Leu	Tyr	Leu	Ser	Gln	Met	Asp	Glu	Asn	Gly	Gly	Ala	Asn	Gln	Tyr	Asr
145					150					155					160
Thr	Ala	Gly	Ala	Asn	Tyr	Gly	Ser	Gly	Tyr	Cys	Asp	Ala	Gln	Cys	Pro
				165					170					175	
Val	Gln	Thr	Trp	Arg	Asn	Gly	Thr	Leu	Asn	Thr	Ser	His	Gln	Gly	Phe
			180					185					190		

Cys Cys Asn Glu Met Asp Ile Leu Glu Gly Asn Ser Arg Ala Asn Ala

- 67 -

Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys Gly Phe Asn Pro Tyr Gly Ser Gly Tyr Lys Ser Tyr Tyr Gly Pro Gly Asp Thr Val Asp Thr Ser Lys Thr Phe Thr Ile Ile Thr Gln Phe Asn Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu Val Ser Ile Thr Arg Lys Tyr Gln Gln Asn Gly Val Asp Ile Pro Ser Ala Gln Pro Gly Gly Asp Thr Ile Ser Ser Cys Pro Ser Ala Ser Ala Tyr Gly Gly Leu Ala Thr Met Gly Lys Ala Leu Ser Ser Gly Met Val Leu Val Phe Ser Ile Trp Asn Asp Asn Ser Gln Tyr Met Asn Trp Leu Asp Ser Gly Asn Ala Gly Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser Asn Ile Leu Ala Asn Asn Pro Asn Thr His Val Val Phe Ser Asn Ile Arg Trp Gly Asp Ile Gly Ser Thr Thr Asn Ser Thr Ala Pro Pro

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1158 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

- 68 -

	(ix) FE	ATUR	Œ:												
		(A) N	IAME/	KEY:	CDS	3									
		(B) L	OCAI	'ION :	joi	n(1.	.56,	231	11	58)					
	(xi) SE	QUEN	CE D	ESCR	IPTI	ON:	SEQ	ID N	0:7:						
GGG	GTC	CGA	TTT	GCC	GGC	GTT	' AAC	ATC	GCG	GGT	TTT	GAC	TTT	GGC	TGT	48
Gly	Val	Arg	Phe	Ala	Gly	Val	Asn	Ile	Ala	Gly	Phe	Asp	Phe	Gly	Cys	
1				5					10					15		
ACC	ACA	GA	GT	GAGT	ACCC	TTG	TTTC	CTG	GTGT	TGCT	GG C	TGGT	TGGG	С		96
Thr	Thr	As	p													
GGGI	ATA	CAG	CGAA	GCGG	AC G	CAAG	AACA	C CG	CCGG	TCCG	CCA	CCAT	CAA	GATG	TGGGTG	156
GTAA	GCG(GCG (GTGT	TTTG	TA C.	AACT.	ACCT	G AC	AGCT	CACT	CAG	GAAA'	TGA (GAAT	TAATGG	216
AAGT	CTT	TT 2	ACAG													264
				G:	ly T	hr C	ys V	al T	hr s	er L	ys V	al T	yr P	ro P	ro	
				:	20				:	25				:	30	
TTG																312
Leu	Lys	Asn	Phe		Gly	Ser	Asn	Asn		Pro	Asp	Gly	Ile	Gly	Gln	
				35					40					45		
N.M.C.	G3.G	63.6														
ATG																360
Met	GIN	HIS		vai	Asn	GIU	Asp		Met	Thr	Ile	Phe		Leu	Pro	
			50					55					60			
													AAT			

WO 95/16360	PCT/EP94/04212

- 69 -

val	GIY	Trp	Gin	Tyr	Leu	. Val	Asn	Asn	Asn	Leu	Gly	Gly	Asn	Leu	Asp	
		65					70					75				
TCC	ACG	AGC	ATT	TCC	AAG	TAT	GAT	CAG	CTT	GTT	CAG	GGG	TGC	CTG	TCT	456
Ser	Thr	Ser	Ile	Ser	Lys	Tyr	Asp	Gln	Leu	Val	Gln	Gly	Cys	Leu	Ser	
	80					85					90					
CTG	GGC	GCA	TAC	TGC	ATC	GTC	GAC	ATC	CAC	AAT	TAT	GCT	CGA	TGG	AAC	504
Leu	Gly	Ala	Tyr	Cys	Ile	Val	Asp	Ile	His	Asn	Tyr	Ala	Arg	Trp	Asn	
95					100					105					110	
GGT	GGG	ATC	ATT	GGT	CAG	GGC	GGC	CCT	ACT	AAT	GCT	CAA	TTC	ACG	AGC	552
Gly	Gly	Ile	Ile	Gly	Gln	Gly	Gly	Pro	Thr	Asn	Ala	Gln	Phe	Thr	Ser	
				115					120					125		
CTT	TGG	TCG	CAG	TTG	GCA	TCA	AAG	TAC	GCA	TCT	CAG	TCG	AGG	GTG	TGG	600
Leu	Trp	Ser	Gln	Leu	Ala	Ser	Lys	Tyr	Ala	Ser	Gln	Ser	Arg	Val	Trp	
		•	130					135					140			
			,													
TTC	GGC	ATC	ATG	AAT	GAG	CCC	CAC	GAC	GTG	AAC	ATC	AAC	ACC	TGG	GCT	648
Phe	Gly	Ile	Met	Asn	Glu	Pro	His	Asp	Val	Asn	Ile	Asn	Thr	Trp	Ala	
		145					150					155				
GCC	ACG	GTC	CAA	GAG	GTT	GTA	ACC	GCA	ATC	CGC	AAC	GCT	GGT	GCT	ACG	696
Ala	Thr	Val	Gln	Glu	Val	Val	Thr	Ala	Ile	Arg	Asn	Ala	Gly	Ala	Thr	
	160					165					170					
TCG	CAA	TTC	ATC	TCT	TTG	CCT	GGA	AAT	GAT	TGG	CAA	TCT	GCT	GGG	GCT	744
Ser	Gln	Phe	Ile	Ser	Leu	Pro	Gly	Asn	Asp	Trp	Gln	Ser	Ala	Gly	Ala	

7	TTC	ATA	TCC	GAT	GGC	AGT	GCA	GCC	GCC	CTG	TCT	CAA	GTC	ACG	AAC	CCG	792
I	Phe	Ile	Ser	Asp	Gly	Ser	Ala	Ala	Ala	Leu	Ser	Gln	Val	Thr	Asn	Pro	
					195					200					205		
C	GAT	GGG	TCA	ACA	ACG	AAT	CTG	ATT	TTT	GAC	GTG	CAC	AAA	TAC	TTG	GAC	840
1	Asp	Gly	Ser	Thr	Thr	Asn	Leu	Ile	Phe	Asp	Val	His	Lys	Tyr	Leu	Asp	
				210					215					220			
7	rca	GAC	AAC	TCC	GGT	ACT	CAC	GCC	GAA	TGT	ACT	ACA	AAT	AAC	ATT	GAC	888
5	Ser	Asp	Asn	Ser	Gly	Thr	His	Ala	Glu	Cys	Thr	Thr	Asn	Asn	Ile	Asp	
			225					230					235				
C	GC.	GCC	TTT	TCT	CCG	CTT	GCC	ACT	TGG	CTC	CGA	CAG	AAC	AAT	CGC	CAG	936
¢	3ly	Ala	Phe	Ser	Pro	Leu	Ala	Thr	Trp	Leu	Arg	Gln	Asn	Asn	Arg	Gln	
		240					245					250					
		240					245					250					
c	ЭСТ		CTG	ACA	GAA	ACC		GGT	GGC	AAC	GTT		TCC	TGC	АТА	CAA	984
		ATC			GAA Glu		GGT					CAG					984
I		ATC					GGT					CAG					984
I	Ala	ATC				Thr	GGT Gly				Val	CAG				Gln	984
2	Ala 255	ATC Ile	Leu	Thr	Glu	Thr 260	GGT Gly	Gly	Gly	Asn	Val 265	CAG Gln	Ser	Cys	Ile	Gln	
2	Ala 255 GAC	ATC Ile	Leu	Thr	Glu	Thr 260	GGT Gly CAA	Gly	Gly	Asn AAC	Val 265 CAG	CAG Gln AAC	Ser	Cys	Ile	Gln 270 TAT	
2	Ala 255 GAC	ATC Ile	Leu	Thr	Glu CAA	Thr 260	GGT Gly CAA	Gly	Gly	Asn AAC	Val 265 CAG	CAG Gln AAC	Ser	Cys	Ile	Gln 270 TAT	
2	Ala 255 GAC	ATC Ile	Leu	Thr	Glu CAA Gln	Thr 260	GGT Gly CAA	Gly	Gly	Asn AAC Asn	Val 265 CAG	CAG Gln AAC	Ser	Cys	Ile GTC Val	Gln 270 TAT	
7 2	Ala 255 GAC Asp	ATC Ile ATG Met	Leu TGC Cys	Thr CAG Gln	Glu CAA Gln	Thr 260 ATC Ile	GGT Gly CAA Gln	Gly TAT Tyr	Gly CTC Leu	AAC Asn 280	Val 265 CAG Gln	CAG Gln AAC Asn	TCA Ser	Cys GAT Asp	Ile GTC Val 285	Gln 270 TAT Tyr	
2	Ala 255 GAC Asp	ATC Ile ATG Met	TGC Cys	Thr CAG Gln	Glu CAA Gln 275	Thr 260 ATC Ile	GGT Gly CAA Gln	Gly TAT Tyr	Gly CTC Leu	ASN AAC ASN 280	Val 265 CAG Gln	CAG Gln AAC Asn	TCA Ser	Cys GAT Asp	Ile GTC Val 285	Gln 270 TAT Tyr	1032
2	Ala 255 GAC Asp	ATC Ile ATG Met	TGC Cys	Thr CAG Gln	Glu CAA Gln 275 GGT	Thr 260 ATC Ile	GGT Gly CAA Gln	Gly TAT Tyr	Gly CTC Leu	ASN AAC ASN 280	Val 265 CAG Gln	CAG Gln AAC Asn	TCA Ser	Cys GAT Asp	Ile GTC Val 285	Gln 270 TAT Tyr	1032
2	Ala 255 GAC Asp	ATC Ile ATG Met	TGC Cys	Thr CAG Gln GTT Val	Glu CAA Gln 275	Thr 260 ATC Ile	GGT Gly CAA Gln	Gly TAT Tyr	Gly CTC Leu GGA	AAC Asn 280	Val 265 CAG Gln	CAG Gln AAC Asn	TCA Ser	GAT Asp ACG	Ile GTC Val 285	Gln 270 TAT Tyr	1032

CTG ACG GAA ACA CCG ACT AGC AGT GGT AAC TCA TGG ACG GAC ACA TCC 1128

- 71 -

Leu Thr Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp Thr Asp Thr Ser

305 310 315

TTG GTC AGC TCG TGT CTC GCA AGA AAG TA

1158

Leu Val Ser Ser Cys Leu Ala Arg Lys

320 325

- (2) INFORMATION FOR SEQ ID NO:8:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 327 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Gly Val Arg Phe Ala Gly Val Asn Ile Ala Gly Phe Asp Phe Gly Cys

1 5 10 15

Thr Thr Asp Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro Leu Lys

20 25 30

Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asp Gly Ile Gly Gln Met Gln

35 40 45

His Phe Val Asn Glu Asp Gly Met Thr Ile Phe Arg Leu Pro Val Gly

50 55 60

Trp Gln Tyr Leu Val Asn Asn Leu Gly Gly Asn Leu Asp Ser Thr

65 70 75 80

- 72 -

Ser Ile Ser Lys Tyr Asp Gln Leu Val Gln Gly Cys Leu Ser Leu Gly

85 90 95

Ala Tyr Cys Ile Val Asp Ile His Asn Tyr Ala Arg Trp Asn Gly Gly

100 105 110

Ile Ile Gly Gln Gly Gly Pro Thr Asn Ala Gln Phe Thr Ser Leu Trp

Ser Gln Leu Ala Ser Lys Tyr Ala Ser Gln Ser Arg Val Trp Phe Gly
130 135 140

Val Gln Glu Val Val Thr Ala Ile Arg Asn Ala Gly Ala Thr Ser Gln

165 170 175

Phe Ile Ser Leu Pro Gly Asn Asp Trp Gln Ser Ala Gly Ala Phe Ile
180 185 190

Ser Asp Gly Ser Ala Ala Ala Leu Ser Gln Val Thr Asn Pro Asp Gly
195 200 205

Ser Thr Thr Asn Leu Ile Phe Asp Val His Lys Tyr Leu Asp Ser Asp
210 215 220

Asn Ser Gly Thr His Ala Glu Cys Thr Thr Asn Asn Ile Asp Gly Ala
225 230 235 240

- 73 -

Phe Ser Pro Leu Ala Thr Trp Leu Arg Gln Asn Asn Arg Gln Ala Ile
245 250 255

Leu Thr Glu Thr Gly Gly Gly Asn Val Gln Ser Cys Ile Gln Asp Met
260 265 270

Cys Gln Gln Ile Gln Tyr Leu Asn Gln Asn Ser Asp Val Tyr Leu Gly
275 280 285

Tyr Val Gly Trp Gly Ala Gly Ser Phe Asp Ser Thr Tyr Val Leu Thr
290 295 300

Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp Thr Asp Thr Ser Leu Val

Ser Ser Cys Leu Ala Arg Lys

325

- 2) INFORMATION FOR SEQ ID NO:9:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 81 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..81
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

- 74 -

CCC CCG CCT GCG TCC AGC ACG ACG TTT TCG ACT ACA CCG AGG AGC TCG

48

Pro Pro Pro Ala Ser Ser Thr Thr Phe Ser Thr Thr Pro Arg Ser Ser

1 5 10 15

ACG ACT TCG AGC AGC CCG AGC TGC ACG CAG ACT

Thr Thr Ser Ser Ser Pro Ser Cys Thr Gln Thr

20 25

- (2) INFORMATION FOR SEQ ID NO:10:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Pro Pro Pro Ala Ser Ser Thr Thr Phe Ser Thr Thr Pro Arg Ser Ser

1 5 10 15

Thr Thr Ser Ser Ser Pro Ser Cys Thr Gln Thr
20 25

- (2) INFORMATION FOR SEQ ID NO:11:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 102 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:

- 75 -

(A) NAME/KEY: CDS

(B) LOCATION: 1..102

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

CCG GGA GCC ACT ACT ATC ACC ACT TCG ACC CGG CCA CCA TCC GGT CCA

48

Pro Gly Ala Thr Thr Ile Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro

1 5 10 15

ACC ACC ACC ACC AGG GCT ACC TCA ACA AGC TCA TCA ACT CCA CCC ACG

96

Thr Thr Thr Thr Arg Ala Thr Ser Thr Ser Ser Ser Thr Pro Pro Thr

20

25

30

AGC TCT

Ser Ser

- (2) INFORMATION FOR SEQ ID NO:12:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 34 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Pro Gly Ala Thr Thr Ile Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro

1 5 10 15

Thr Thr Thr Arg Ala Thr Ser Thr Ser Ser Ser Thr Pro Pro Thr

20 25 30

Ser Ser

- 76 -

- 76 -	
(2) INFORMATION FOR SEQ ID NO:13:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 66 base pairs	
(B) TYPE: nucleic acid	
(C) STRANDEDNESS: single	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: DNA (genomic)	
(ix) FEATURE:	
(A) NAME/KEY: CDS	
(B) LOCATION: 166	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	
ATG GCG CCC TCA GTT ACA CTG CCG TTG ACC ACG GCC ATC CTG GCC ATT	48
Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile Leu Ala Ile	
1 5 10 15	
GCC CGG CTC GCC GCC	56
Ala Arg Leu Val Ala Ala	
20	
(2) INFORMATION FOR SEQ ID NO:14:	
(i) SEQUENCE CHARACTERISTICS:	
(A) LENGTH: 22 amino acids	
(B) TYPE: amino acid	
(D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: protein	
(vi) CECTENCE DECEPTOTION, SEC ID NO.14.	

Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile Leu Ala Ile

1 5 10 15

- 77 -

Ala Arg Leu Val Ala Ala

20

- (2) INFORMATION FOR SEQ ID NO:15:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 63 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..63
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATG AAC AAG TCC GTG GCT CCA TTG CTG CTT GCA GCG TCC ATA CTA TAT

48

Met Asn Lys Ser Val Ala Pro Leu Leu Ala Ala Ser Ile Leu Tyr

1 5 10 15

63

Gly Gly Ala Val Ala

GGC GGC GCC GTC GCA

20

- (2) INFORMATION FOR SEQ ID NO:16:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein

- 78 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser Ile Leu Tyr

1 5 10 15

Gly Gly Ala Val Ala

20

- (2) INFORMATION FOR SEQ ID NO:17:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 777 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AAACCAGCTG TGACCAGTGG GCAACCTTCA CTGGCAACGG CTACACAGTC AGCAACAACC 60

TTTGGGGAGC ATCAGCCGGC TCTGGATTTG GCTGCGTGAC GGCGGTATCG CTCAGCGGCG 120

GGGCCTCCTG GCACGCAGAC TGGCAGTGGT CCGGCGGCCA GAACAACGTC AAGTCGTACC 180

AGAACTCTCA GATTGCCATT CCCCAGAAGA GGACCGTCAA CAGCATCAGC AGCATGCCCA 240

CCACTGCCAG CTGGAGCTAC AGCGGGAGCA ACATCCGCGC TAATGTTGCG TATGACTTGT 300

TCACCGCAGC CAACCCGAAT CATGTCACGT ACTCGGGAGA CTACGAACTC ATGATCTGGT 360

AAGCCATAAG AAGTGACCCT CCTTGATAGT TTCGACTAAC AACATGTCTT GAGGCTTGGC

420

- 79 -

AAATACGGCG	ATATTGGGCC	GATTGGGTCC	TCACAGGGAA	CAGTCAACGT	CGGTGGCCAG	480
AGCTGGACGC	TCTACTATGG	CTACAACGGA	GCCATGCAAG	TCTATTCCTT	TGTGGCCCAG	540
ACCAACACTA	CCAACTACAG	CGGAGATGTC	AAGAACTTCT	TCAATTATCT	CCGAGACAAT	600
AAAGGATACA	ACGCTGCAGG	CCAATATGTT	CTTAGTAAGT	CACCCTCACT	GTGACTGGGC	660
TGAGTTTGTT	GCAACGTTTG	CTAACAAAAC	CTTCGTATAG	GCTACCAATT	TGGTACCGAG	720
CCCTTCACGG	GCAGTGGAAC	TCTGAACGTC	GCATCCTGGA	CCGCATCTAT	CAACTAA	777
	CION FOR SEC					

- (A) LENGTH: 218 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Gln Thr Ser Cys Asp Gln Trp Ala Thr Phe Thr Gly Asn Gly Tyr Thr

1 5 10 15

Val Ser Asn Asn Leu Trp Gly Ala Ser Ala Gly Ser Gly Phe Gly Cys

20 25 30

Val Thr Ala Val Ser Leu Ser Gly Gly Ala Ser Trp His Ala Asp Trp

35 40 45

WO 95/16360

- 80 -

PCT/EP94/04212

Gln Trp Ser Gly Gly Gln Asn Asn Val Lys Ser Tyr Gln Asn Ser Gln
50 55 60

Ile Ala Ile Pro Gln Lys Arg Thr Val Asn Ser Ile Ser Ser Met Pro
65 70 75 80

Thr Thr Ala Ser Trp Ser Tyr Ser Gly Ser Asn Ile Arg Ala Asn Val

Ala Tyr Asp Leu Phe Thr Ala Ala Asn Pro Asn His Val Thr Tyr Ser

Gly Asp Tyr Glu Leu Met Ile Trp Leu Gly Lys Tyr Gly Asp Ile Gly
115 120 125

Pro Ile Gly Ser Ser Gln Gly Thr Val Asn Val Gly Gln Ser Trp

130 135 140

Thr Leu Tyr Tyr Gly Tyr Asn Gly Ala Met Gln Val Tyr Ser Phe Val
145 150 155 160

Ala Gln Thr Asn Thr Thr Asn Tyr Ser Gly Asp Val Lys Asn Phe Phe 165 170 175

Asn Tyr Leu Arg Asp Asn Lys Gly Tyr Asn Ala Ala Gly Gln Tyr Val

Leu Ser Tyr Gln Phe Gly Thr Glu Pro Phe Thr Gly Ser Gly Thr Leu
195 200 205

- 81 -

Asn Val Ala Ser Trp Thr Ala Ser Ile Asn 210 215

- (2) INFORMATION FOR SEQ ID NO:19:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 46 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

ATGAAGTTCC TTCAAGTCCT CCCTGCCCTC ATACCGGCCG CCCTGGCCC

49

- (2) INFORMATION FOR SEO ID NO:20:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met Lys Phe Leu Gln Val Leu Pro Ala Leu Ile Pro Ala Ala Leu Ala

1 5 10 15

- (2) INFORMATION FOR SEQ ID NO:21:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 57 base pairs

- 82 -

57

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGCTCGTAGA GCGTTGACTT GCCTGTGGTC TGTCCAGACG GGGGACGATA GAATGCG

Claims:

- 1. The use of a composition as a feed additive which comprises one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the composition, of a cellobiohydrolase.
- 2. The use according to claim 1, wherein the composition is free of any cellobiohydrolase.
- 3. The use according to claim 1 or claim 2, wherein the one or more endoglucanases are obtainable from a fungal source.
- 4. The use according to any preceding claim, wherein the feed additive comprises at least one of EGI, EGII, EGIII, or a derivative of any thereof.
- 5. The use according to any preceding claim, wherein the endoglucanase(s) is/are obtainable from a genetically modified strain of the fungus *Trichoderma*.
- 6. The use according to claim 5, wherein the genetically modified strain is derived T.longibrachiatum, T. reesei or T. viride whose genome has been modified so that it is enriched in its production of one or more endoglucanases and/or unable to produce one or more functionally active cellobiohydrolases.
- 7. The use according to claim 6, wherein the genome of the genetically modified strain is also unable to produce functionally active EGI and/or EGII.

- 84 -

- 8. The use according to any of claims 1-6, wherein the one or more endoglucanases are EGI which lacks the cellulose binding domain and/or EGII which lacks the cellulose binding domain.
- 9. An enzyme-based feed additive which comprises at least one of EGIII, EGI which lacks the cellulose binding domain and EGII which lacks the cellulose binding domain, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.
- 10. An enzyme-based feed additive comprising a cereal-based carrier, one or more endoglucanases, and 0-20% by weight, based upon the content of cellulase proteins in the additive, of a cellobiohydrolase.
- 11. An enzyme-based feed additive according to claim 10, wherein the cereal-based carrier is one or more of milled wheat, maize, milled soya or a by-product of any of these materials.
- 12. An enzyme-based feed additive according to any of claims 9-11, wherein the additive further comprises one or more additional enzymes selected from a xylanase, a protease, an α -amylase, a glucoamylase, a lipase, a pectinase, a mannanase, an α -galactosidase, an α -arabinofuranosidase, an α -arabinofuranosidase and a phytase.

- 85 -

- 13. An enzyme-based feed additive according to claim 12, wherein the xylanase is the high pI xylanase and/or the low pI xylanase of T. longibrachiatum.
- 14. An enzyme-based feed additive according to claim 12 or claim 13, wherein the protease is a subtilisin or mutant thereof derived from the genus *Bacillus*.
- 15. A cereal-based animal feed comprising at least one cereal selected from barley, wheat, triticale, rye and maize, and an enzyme-based feed additive according to any of claims 9-14.
- 16. The use of a cereal-based feed according to claim15, for feeding poultry.

TGTGTTGAAATCCAACTTATAAAGACAACCACCGCAAACTTTGTCTTGTG	5 0
CCATCAGATTGTTGCCAAGCACCGTCCCCCCCCCCTATCTTAGTCCTTCT	50
TGTTGTCCCAAAATGGCGCCCTCAGTTACACTGCCGTTGACCACGGCCAT	100
Met Ala Pro Ser Val Thr Leu Pro Leu Thr Thr Ala Ile	150
Leu Ala IIe Ala Arg Leu Val Ala Ala Gin Gin Pro Giy Thr Ser Thr CCGAGGTCCATCCCAAGTTGACAACCTACAAGTGTACAAAGTCCGGGGGG	250
Pro Glu Val His Pro Lys Leu Thr Thr Tyr Lys Cys Thr Lys Ser Gly Gly TGCGTGGCCCAGGACACCTCGGTGGTCCTTGACTGGAACTACCGCTGGAT	300
Cys Val Ala Gln Asp Thr Ser Val Val Leu Asp Trp Asn Tyr Arg Trp Met GCACGACGCAAACTACAACTCGTGCACCGTCAACGGCGGCGTCAACACCCA	350
His Asp Ala Asn Tyr Asn Ser Cys Thr Val Asn Gly Gly Val Asn Thr CGCTCTGCCCTGACGAGGCGACCTGTGGCAAGAACTGCTTCATCGAGGGC	400
Thr Leu Cys Pro Asp Glu Ala Thr Cys Gly Lys Asn Cys Phe Ile Glu Gly GTCGACTACGCCGCCTCGGGCGTCACGACCTCGGGCAGCAGCCTCACCAT	450
Val Asp Tyr Ala Ala Ser Gly Val Thr Thr Ser Gly Ser Ser Leu Thr Met GAACCAGTACATGCCCAGCAGCTCTTGGCGGCTACAGCAGCGTCTCTCCTC	500
Asn Gin Tyr Met Pro Ser Ser Ser Gly Gly Tyr Ser Ser Val Ser Pro GGCTGTATCTCCTGGACTCTGACGGTGAGTACGTGATGCTGAAGCTCAAC	550
Arg Leu Tyr Leu Leu Asp Ser Asp Gly Glu Tyr Val Met Leu Lys Leu Asn GGCCAGGAGCTGAGCTTCGACGTCGACCTCTCTGCTCTG	600
Gly Gln Glu Leu Ser Phe Asp Val Asp Leu Ser Ala Leu Pro Cys Gly Glu GAACGGCTCGCTCTACCTGTCTCAGATGGACGAGAACGGGGGCGCCAACC	650
Asn Gly Ser Leu Tyr Leu Ser Gln Met Asp Glu Asn Gly Gly Ala Asn AGTATAACACGGCCGGTGCCAACTACGGGAGCGGCTACTGCGATGCTCAG	700
GIN TYR ASN THR AID GIY AID ASN TYR GIY SER GIY TYR CYS ASP AID GIN TGCCCCGTCCAGACATGGAGGAACGGCACCCTCAACACTAGCCACCAGGG	
Cys Pro Val Gln Thr Trp Arg Asn Gly Thr Leu Asn Thr Ser His Gln Gly CTTCTGCTGCAACGAGATGGATATCCTGGAGGGCAACTCGAGGGCGAATG	750
Phe Cys Cys Asn Glu Met Asp IIe Leu Glu Gly Asn Ser Arg Ala Asn	800

FIG. 1A

CCTTGACCCCTCACTCTTGCACGGCCACGGCCTGCGACTCTGCCGGTTGC	850
Ala Leu Thr Pro His Ser Cys Thr Ala Thr Ala Cys Asp Ser Ala Gly Cys GGCTTCAACCCCTATGGCAGCGGCTACAAAAGGTGAGCCTGATGCCACTA	
Gly Phe Asn Pro Tyr Gly Ser Gly Tyr Lys Ser	900
CTACCCCTTTCCTGGCGCTCTCGCGGTTTTCCATGCTGACATGGTTTTCC	950
AGCTACTACGGCCCGGAGATACCGTTGACACCTCCAAGACCTTCACCAT	1000
Tyr Tyr Gly Pro Gly Asp Thr Val Asp Thr Ser Lys Thr Phe Thr Ile CATCACCCAGTTCAACACGGACAACGGCTCGCCCTCGGGCAACCTTGTGA	1000
Ile Thr Gln Phe Asn Thr Asp Asn Gly Ser Pro Ser Gly Asn Leu Val GCATCACCCGCAAGTACCAGCAAAACGGCGTCGACATCCCCAGCGCCCAG	1100
Ser Ile Thr Arg Lys Tyr Gln Gln Asn Gly Val Asp Ile Pro Ser Ala Gln CCCGGCGGCGACACCATCTCGTCCTGCCCGTCCGCCTCAGCCTACGGCGG	
Pro Gly Gly Asp Thr Ile Ser Ser Cys Pro Ser Ala Ser Ala Tyr Gly Gly CCTCGCCACCATGGGCAAGGCCCTGAGCAGCGGCATGGTGCTCGTGTTCA	1150
Leu Ala Thr Met Gly Lys Ala Leu Ser Ser Gly Met Val Leu Val Phe GCATTTGGAACGACAACAGCCAGTACATGAACTGGCTCGACAGCGGCAAC	1200 1250
Ser IIe Trp Asn Asp Asn Ser Gin Tyr Met Asn Trp Leu Asp Ser Giy Asn GCCGGCCCCTGCAGCACCCGAGGGCAACCCATCCAACATCCTGGCCAA	1300
Ala Gly Pro Cys Ser Ser Thr Glu Gly Asn Pro Ser Asn Ile Leu Ala Asn CAACCCCAACACGCACGTCGTCTTCTCCAACATCCGCTGGGGAGACATTG	
Asn Pro Asn Thr His Val Val Phe Ser Asn Ile Arg Trp Gly Asp Ile GGTCTACTACGAACTCGACTGCGCCCCCGCCCCGCCTGCGTCCAGCACG	1400
Gly Ser Thr Thr Asn Ser Thr Ala Pro Pro Pro Pro Pro Ala Ser Ser Thr ACGTTTTCGACTACACCGAGGAGCTCGACGACTTCGAGCAGCCCGAGCTG	1450
Thr Phe Ser Thr Thr Pro Arg Ser Ser Thr Thr Ser Ser Pro Ser Cys CACGCAGACTCACTGGGGGCAGTGCGGTGGCATTGGGTACAGCGGGTGCA	1500
Thr Gln Thr His Trp Gly Gln Cys Gly Gly Ile Gly Tyr Ser Gly Cys AGACGTGCACGTCGGGCACTACGTGCCAGTATAGCAACGACTGTTCGTAT	
Lys Thr Cys Thr Ser Gly Thr Thr Cys Gln Tyr Ser Asn Asp	1550

FIG. 1B





FIG. 1C



IGCCATTTCTGACCTGGATAGGTTTTCCTATGGTCATTCCTATAAGAGAC	50
ACGCTCTTTCGTCGGCCCGTAGATATCAGATTGGTATTCAGTCGCACAGA	100
CGAAGGTGAGTTGATCCTCCAACATGAGTTCTATGAGCCCCCCCTTGCC	150
CCCCCCGTTCACCTTGACCTGCAATGAGAATCCCACCTTTTACAAGAGC	
ATCAAGAAGTATTAATGGCGCTGAATAGCCTCTGCTCGATAATATCTCCC	200
CGTCATCGACAATGAACAAGTCCGTGGCTCCATTGCTGCTTGCAGCGTCC	250
Met Asn Lys Ser Val Ala Pro Leu Leu Leu Ala Ala Ser ATACTATATGGCGGCGCCGTCGCACAGCAGACTGTCTGGGGCCAGTGTGG	300
Ile Leu Tyr Gly Gly Ala Val Ala Gln Gln Thr Val Trp Gly Gln Cys Gly AGGTATTGGTTGGAGCGGACCTACGAATTGTGCTCCTGGCTCAGCTTGTT	350 , 400
Gly Ile Gly Trp Ser Gly Pro Thr Asn Cys Ala Pro Gly Ser Ala Cys CGACCCTCAATCCTTATTATGCGCAATGTATTCCGGGAGCCACTACTATC	450
Ser Thr Leu Asn Pro Tyr Tyr Ala Gln Cys IIe Pro Gly Ala Thr Thr IIe ACCACTTCGACCCGGCCACCATCCGGTCCAACCACCACCACCAGGGCTAC	500
Thr Thr Ser Thr Arg Pro Pro Ser Gly Pro Thr Thr Thr Arg Ala Thr CTCAACAAGCTCATCAACTCCACCCACGAGCTCTGGGGTCCGATTTGCCG	
Ser Thr Ser Ser Ser Thr Pro Pro Thr Ser Ser Gly Val Arg Phe Ala GCGTTAACATCGCGGGTTTTGACTTTGGCTGTACCACAGAGTGAGT	600
Gly Val Asn Ile Ala Gly Phe Asp Phe Gly Cys Thr Thr Asp	600
TTGTTTCCTGGTGTTGCTGGCTGGTTGGGCGGGTATACAGCGAAGCGGAC	650
GCAAGAACACCGCCGGTCCGCCACCATCAAGATGTGGGTGG	700
GTGTTTTGTACAACTACCTGACAGCTCACTCAGGAAATGAGAATTAATGG	750
AAGTCTTGTTACAGTGGCACTTGCGTTACCTCGAAGGTTTATCCTCCGTT	800
Gly Thr Cys Val Thr Ser Lys Val Tyr Pro Pro Leu GAAGAACTTCACCGGCTCAAACAACTACCCCGATGGCATCGCCCAGATGC	850
Lys Asn Phe Thr Gly Ser Asn Asn Tyr Pro Asn Gly Lie Gly Cin Met	


FIG. 2A

AGCACTTCGTCAACGAGGACGGGATGACTATTTTCCGCTTACCTGTCGGA	000
Gln His Phe Val Asn Glu Asp Gly Met Thr IIe Phe Arg Leu Pro Val Gly TGGCAGTACCTCGTCAACAACAATTTGGGCGGCAATCTTGATTCCACGAG	900
Trp Gin Tyr Leu Val Asn Asn Asn Leu Gly Gly Asn Leu Asp Ser Thr Ser CATTTCCAAGTATGATCAGCTTGTTCAGGGGTGCCTGTCTCTGGGCGCAT	
Ile Ser Lys Tyr Asp Gin Leu Vai Gin Gly Cys Leu Ser Leu Gly Ala ACTGCATCGTCGACATCCACAATTATGCTCGATGGAACGGTGGGATCATT	1000
Tyr Cys lle Val Asp Ile His Asn Tyr Ala Arg Trp Asn Gly Gly Ile Ile GGTCAGGGCGGCCCTACTAATGCTCAATTCACGAGCCTTTGGTCGCAGTT	1050
Gly Gln Gly Gly Pro Thr Asn Ala Gln Phe Thr Ser Leu Trp Ser Gln Leu GGCATCAAAGTACGCATCTCAGTCGAGGGTGTGGTTCGGCATCATGAATG	
Ala Ser Lys Tyr Ala Ser Gin Ser Arg Val Trp Phe Giy Ile Met Asn AGCCCCACGACGTGAACATCAACACCTGGGCTGCCACGGTCCAAGAGGTT	1150
Glu Pro His Asp Val Asn IIe Asn Thr Trp Ala Ala Thr Val Gin Glu Val GTAACCGCAATCCGCAACGCTGGTGCTACGTCGCAATTCATCTCTTTGCC	1200
Val Thr Ala IIe Arg Asn Ala Gly Ala Thr Ser Gln Phe IIe Ser Leu Pro TGGAAATGATTGGCAATCTGCTGGGGCTTTCATATCCGATGGCAGTGCAG	
Gly Asn Asp Trp Gln Ser Ala Gly Ala Phe Ile Ser Asp Gly Ser Ala CCGCCCTGTCTCAAGTCACGAACCCGGATGGGTCAACAACGAATCTGATT	1300
Ala Ala Leu Ser Gin Vai Thr Asn Pro Asp Giy Ser Thr Thr Asn Leu Ile TTTGACGTGCACAAATACTTGGACTCAGACAACTCCGGTACTCACGCCGA	1350
Phe Asp Val His Lys Tyr Leu Asp Ser Asp Asn Ser Gly Thr His Ala Glu ATGTACTACAAATAACATTGACGGCGCCTTTTCTCCGCTTGCCACTTGGC	1400
Cys Thr Thr Asn Asn IIe Asp Gly Ala Phe Ser Pro Leu Ala Thr Trp TCCGACAGAACAATCGCCAGGCTATCCTGACAGAAACCGGTGGTGGCAAC	1450
eu Arg Gin Asn Asn Arg Gin Ala IIe Leu Thr Giu Thr Giy Giy Asn GTTCAGTCCTGCATACAAGACATGTGCCAGCAAATCCAATATCTCAACCA	1500
Val Gin Ser Cys Ile Gin Asp Met Cys Gin Gin Ile Gin Tyr Leu Asn Gin GAACTCAGATGTCTATCTTGGCTATGTTGGTTGGGGTGCCGGATCATTTG	1550
Asn Ser Asp Val Tyr Leu Gly Tyr Val Gly Trp Gly Ala Gly Ser Phe	1600

FIG. 2B

ATAGCACGTATGTCCTGACGGAAACACCGACTAGCAGTGGTAACTCATGG	1650
Asp Ser Thr Tyr Val Leu Thr Glu Thr Pro Thr Ser Ser Gly Asn Ser Trp ACGGACACATCCTTGGTCAGCTCGTGTCTCGCAAGAAAGTAGCACTCTGA	
Thr Asp Thr Ser Leu Val Ser Ser Cys Leu Ala Arg Lys • GCTGAATGCAGAAGCCTCGCCAACGTTTGTATCTCGCTATCAAACATAGT	1700 1750
AGCTACTCTATGAGGCTGTCTGTTCTCGATTTCAGCTTTATATAGTTTCA	1800
TCAAACAGTACATATTCCCTCTGTGGCCACGCAAAAAAAA	1849

FIG. 2C





GGGTGGTCTGGATGAAACGTCTTGGCCAAATCGTGATCGATTGATACTCG	ΕO
CATCTATAAGATGGCACAGATCGACTCTTGATTCACAGACATCCGTCAGC	50 100
CCTCAAGCCGTTTGCAAGTCCACAAACACAAGCACAAGCATAGCGTCGCA	150
ATGAAGTTCCTTCAAGTCCTCCCTGCCCTCATACCGGCCGCCCTGGCCCA	200
Met Lys Phe Leu Gin Val Leu Pro Ala Leu IIe Pro Ala Ala Leu Ala Gin	200
AACCAGCTGTGACCAGTGGGCAACCTTCACTGGCAACGGCTACACAGTCA	250
Thr Ser Cys Asp Gln Trp Ala Thr Phe Thr Gly Asn Gly Tyr Thr Val	250
GCAACAACCTTTGGGGAGCATCAGCCGGCTCTGGATTTGGCTGCGTGACG	300
Ser Asn Asn Leu Trp Gly Ala Ser Ala Gly Ser Gly Phe Gly Cys Val Thr	300
GCGGTATCGCTCAGCGGCGGGGCCTCCTGGCACGCAGACTGGCAGTGGTC	350
Ala Val Ser Leu Ser Gly Gly Ala Ser Trp His Ala Asp Trp Gln Trp Ser	350
CGGCGGCCAGAACACGTCAAGTCGTACCAGAACTCTCAGATTGCCATTC	400
Gly Gly Gln Asn Asn Val Lys Ser Tyr Gln Asn Ser Gln Ile Ala Ile	400
CCCAGAAGAGGACCGTCAACAGCATCAGCAGCATGCCCACCACTGCCAGC	<i>".</i> = 0
Pro Gln Lys Arg Thr Val Asn Ser Ile Ser Ser Met Pro Thr Thr Ala Ser	450
TGGAGCTACAGCGGGAGCAACATCCGCGCTAATGTTGCGTATGACTTGTT	500
Trp Ser Tyr Ser Gly Ser Asn Ile Arg Ala Asn Val Ala Tyr Asp Leu Phe	300
CACCGCAGCCAACCCGAATCATGTCACGTACTCGGGAGACTACGAACTCA	550
Thr Ala Ala Asn Pro Asn His Val Thr Tyr Ser Gly Asp Tyr Glu Leu	330
TGATCTGGTAAGCCATAAGAAGTGACCCTCCTTGATAGTTTCGACTAACA	600
Met Ile Trp	

FIG. 3 **A**

ACATGTCTTGAGGCTTGGCAAATACGGCGATATTGGGCCGATTGGGTCCT	650		
Leu Gly Lys Tyr Gly Asp Ile Gly Pro Ile Gly Ser	050		
CACAGGGAACAGTCAACGTCGGTGGCCAGAGCTGGACGCTCTACTATGGC	700		
Ser Gln Gly Thr Val Asn Val Gly Gly Gln Ser Trp Thr Leu Tyr Tyr Gly	700		
TACAACGGAGCCATGCAAGTCTATTCCTTTGTGGCCCAGACCAACACTAC	750		
Tyr Asn Gly Ala Met Gin Val Tyr Ser Phe Val Ala Gin Thr Asn Thr Thr			
CAACTACAGCGGAGATGTCAAGAACTTCTTCAATTATCTCCGAGACAATA	800		
Asn Tyr Ser Gly Asp Val Lys Asn Phe Phe Asn Tyr Leu Arg Asp Asn	800		
AAGGATACAACGCTGCAGGCCAATATGTTCTTAGTAAGTCACCCTCACTG	850		
Lys Gly Tyr Asn Ala Ala Gly Gln Tyr Val Leu Ser	030		
TGACTGGGCTGAGTTTGTTGCAACGTTTGCTAACAAAACCTTCGTATAGG	900		
	000		
CTACCAATTTGGTACCGAGCCCTTCACGGGCAGTGGAACTCTGAACGTCG	950		
Tyr Gin Phe Gly Thr Glu Pro Phe Thr Gly Ser Gly Thr Leu Asn Val	550		
CATCCTGGACCGCATCTATCAACTAAAACCTGGAAACGTGAGATGTGGTG	1000		
Ala Ser Trp Thr Ala Ser Ile Asn •			
GGCATACGTTATTGAGCGAGGGAAAAAAAGCATTGGATCCATTGAAGATG	1050		

FIG. 3**B**






- Digest with BsmI and EcoRI
- Isolate 300bp BsmI/EcoRI Fragment
- Digest pUC218 with SstI and EcoRI
- Ligate pUC218 SstI/EcoRI and BamI/EcoRI fragment with the following synthetic oligonucleotides

(SEQ. ID NO:37)

CGTAGAGCGTTGACTTGCCTGTGGTCTGTCCAGACGGGGGACGATAGAATGCG TCGAGCATCTCGCAACTGAACGGACACCAGACAGGTCTGCCCCCTGCTATCTTAC SstI BsmI




- Digest pEG1T with HindIII and BsmI and Isolate vector fragment
- Digest pUC218::EG1 with HindIII and SstI and Isolate 2.3 kb EG1 fragment
- Ligate pEG1T HindIII/BsmI and 2.3 Kb HindIII/SstI with the following synthetic oligonucleotides

CGTAGAGCGTTGACTTGCCTGTGGTCTGTCCAGACGGGGGACGATAGAATGCG TCGAGCATCTCGCAACTGAACGGACACCAGACAGGTCTGCCCCCTGCTATCTTAC SstI


FIG. 4 A

SUBSTITUTE SHEET (RULE 26)



- Digest p219M with EcoRI and HindIII
- Isolate 1.6Kb EcoRI/HindIII pyr4 gene fragment
- Digest pUC218 with EcoRI SstI and dephosphorylate the ends with calf alkaline phosphotase

EcoRI






FIG 5

Interr 1al Application No PCT/EP 94/04212

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A23K1/165 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category * 1-9 WO,A,91 18090 (OY ALKO AB) 28 November X see page 35, line 15 - line 20 see examples 1-3 see claims 1-3,7-11,13 10-16 Υ 10-16 WO,A,91 04673 (NOVO NORDISK A/S) 18 April Y 1991 cited in the application see page 3, line 21 - page 4, line 7 see examples 1-3,6 see claims 1-5 Patent family members are listed in annex. Further documents are listed in the continuation of box C. * Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 2 4. 04. 95 5 April 1995 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Dekeirel, M

1

Inter: IAI Application No
PCT/EP 94/04212

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
х	WO,A,93 20714 (SSV-DEVELOPMENT OY) 28 October 1993 see page 1, line 5 - line 16 see page 5, line 13 - line 20 see page 6, line 26 - page 7, line 19 see page 8, line 2 - page 9, line 8 see page 10, line 5 - line 21 see page 26, line 17 - line 20 see examples 1,4 see claims 1-39	1-16
X	WO,A,90 09436 (CARLSBERG A/S) 23 August 1990 see page 5, line 28 - page 6, line 6 see claims 66,67	1,9,15, 16
X	JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE., vol.63, no.1, 1993, BARKING GB pages 107 - 108 M. R. BEDFORD 'Feed enzymes in barley-based diets' see page 107, column 1, last paragraph - page 108, column 2, paragraph 2	1,9,15, 16
A	WO,A,92 06184 (GENENCOR INTERNATIONAL, INC.) 16 April 1992 see page 28, line 11 - line 17	1-7
A	WO,A,92 06209 (GENENCOR INTERNATIONAL INC.) 16 April 1992 cited in the application see the whole document	1-8

Information on patent family members

Intern al Application No
PCT/EP 94/04212

Patent document cited in search report	Publication date		t family iber(s)	Publication date
WO-A-9118090	28-11-91	US-A- AU-A- EP-A-	5298405 7869891 0532533	29-03-94 10-12-91 24-03-93
WO-A-9104673	18-04-91	DE-D- DE-T- EP-A- JP-T-	69007115 69007115 0494916 5500807	07-04-94 09-06-94 22-07-92 18-02-93
WO-A-9320714	28-10-93	AU-B- CA-A- EP-A- FI-A- NO-A-	3954093 2133748 0634899 944724 943782	18-11-93 28-10-93 25-01-95 07-10-94 09-12-94
WO-A-9009436	23-08-90	AU-B- AU-A- CA-A- EP-A- JP-T-	638695 5101390 2050468 0458846 5504462	08-07-93 05-09-90 17-08-90 04-12-91 15-07-93
WO-A-9206184	16-04-92	US-A- CA-A- EP-A- US-A-	5290474 2093423 0586375 5328841	01-03-94 01-12-92 16-03-94 12-07-94
WO-A-9206209	16-04-92	CA-A- CA-A- CA-A- EP-A- EP-A- EP-A- FI-A- FI-A- JP-T- JP-T- JP-T-	2093421 2093424 2093428 0551386 0551394 0552276 0553280 931490 931491 931495 6502223 6502205 6511379 6502226	06-04-92 06-04-92 06-04-92 21-07-93 21-07-93 28-07-93 04-08-93 31-05-93 25-05-93 27-05-93 10-03-94 10-03-94 10-03-94

Information on patent family members

Interns al Application No
PCT/EP 94/04212

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9206209		WO-A- WO-A- WO-A- US-A- US-A- US-A-	9206210 9206221 9206183 5246853 5290474 5328841	16-04-92 16-04-92 16-04-92 21-09-93 01-03-94 12-07-94

Form PCT/ISA/210 (patent family annex) (July 1992)